The University of Chicago Header Logo

Marina Chiara Garassino

TitleProfessor
InstitutionUniversity of Chicago
DepartmentMedicine-Hematology and Oncology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Paz-Ares L, Garassino MC, Chen Y, Reinmuth N, Hotta K, Poltoratskiy A, Trukhin D, Hochmair MJ, Özgüroglu M, Ji JH, Statsenko G, Conev N, Bondarenko I, Havel L, Losonczy G, Xie M, Lai Z, Godin-Heymann N, Mann H, Jiang H, Shrestha Y, Goldman JW, Paz-Ares L, Garassino MC, Chen Y, Reinmuth N, Poltoratskiy A, Trukhin D, Hochmair MJ, Özgüroglu M, Ji JH, Statsenko G, Conev N, Bondarenko I, Havel L, Losonczy G, Xie M, Lai Z, Godin-Heymann N, Mann H, Jiang H, Shrestha Y, Goldman JW. Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden. Clin Cancer Res. 2024 Feb 16; 30(4):824-835. PMID: 37801329; PMCID: PMC10870117.
      Citations: 1     Fields:    
    2. Ndembe G, Intini I, Moro M, Grasselli C, Panfili A, Panini N, Bleve A, Occhipinti M, Borzi C, Garassino MC, Marabese M, Canesi S, Scanziani E, Sozzi G, Broggini M, Ganzinelli M. Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy. J Exp Clin Cancer Res. 2024 Jan 02; 43(1):6. PMID: 38163906; PMCID: PMC10759660.
      Citations:    Fields:    Translation:HumansAnimals
    3. Garassino MC, Faivre-Finn C. Response to Letter to the Editor From Shaorong Yu and Jifeng Feng. J Thorac Oncol. 2024 Jan; 19(1):174-175. PMID: 38185512.
      Citations:    Fields:    
    4. Gridelli C, Peters S, Mok T, Garassino M, Paz-Ares L, Attili I, de Marinis F. Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT). Lung Cancer. 2024 Jan; 187:107441. PMID: 38141488.
      Citations:    Fields:    Translation:Humans
    5. Tan DSW, Felip E, de Castro G, Solomon BJ, Greystoke A, Cho BC, Cobo M, Kim TM, Ganguly S, Carcereny E, Paz-Ares L, Bennouna J, Garassino MC, Schenker M, Kim SW, Brase JC, Bury-Maynard D, Passos VQ, Deudon S, Dharan B, Song Y, Caparica R, Johnson BE. Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial. J Clin Oncol. 2024 Jan 10; 42(2):192-204. PMID: 38039427.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    6. Burns L, Hsu CY, Whisenant JG, Marmarelis ME, Presley CJ, Reckamp KL, Khan H, Jo Fidler M, Bestvina CM, Brahmer J, Puri S, Patel JD, Halmos B, Hirsch FR, Liu SV, Costa DB, Goldberg SB, Feldman LE, Mamdani H, Puc M, Mansfield AS, Islam N, Scilla KA, Garassino MC, Horn L, Peters S, Wakelee HA, Charlot M, Tapan U. Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT). Lung Cancer. 2023 12; 186:107423. PMID: 37995456.
      Citations:    Fields:    Translation:Humans
    7. Le X, Paz-Ares LG, Van Meerbeeck J, Viteri S, Galvez CC, Smit EF, Garassino M, Veillon R, Baz DV, Pradera JF, Sereno M, Kozuki T, Kim YC, Yoo SS, Han JY, Kang JH, Son CH, Choi YJ, Stroh C, Juraeva D, Vioix H, Bruns R, Otto G, Johne A, Paik PK. Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B. Cell Rep Med. 2023 11 21; 4(11):101280. PMID: 37944528; PMCID: PMC10694660.
      Citations: 2     Fields:    Translation:Humans
    8. Liu SV, Mok TSK, Nabet BY, Mansfield AS, De Boer R, Losonczy G, Sugawara S, Dziadziuszko R, Krzakowski M, Smolin A, Hochmair MJ, Garassino MC, Gay CM, Heymach JV, Byers LA, Lam S, Cardona A, Morris S, Adler L, Shames DS, Reck M. Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide. Lung Cancer. 2023 12; 186:107418. PMID: 37931445.
      Citations:    Fields:    Translation:Humans
    9. Manglaviti S, Bini M, Apollonio G, Zecca E, Galli G, Sangaletti S, Labianca A, Sottotetti E, Brambilla M, Occhipinti M, Proto C, Prelaj A, Signorelli D, De Toma A, Viscardi G, Beninato T, Mazzeo L, Bottiglieri A, Leporati R, Fotia G, Ganzinelli M, Portararo P, Garassino MC, de Braud FGM, Lo Russo G, Torri V, Ferrara R. High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors. Lung Cancer. 2023 12; 186:107417. PMID: 37918061.
      Citations:    Fields:    Translation:Humans
    10. Nuccio A, Viscardi G, Salomone F, Servetto A, Venanzi FM, Riva ST, Oresti S, Ogliari FR, Viganò M, Bulotta A, Cameron R, Esposito A, Hines J, Bianco R, Reni M, Cascone T, Garassino MC, Torri V, Veronesi G, Cinquini M, Ferrara R. Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies. Eur J Cancer. 2023 12; 195:113404. PMID: 37948842.
      Citations:    Fields:    Translation:Humans
    11. Cameron RB, Hines JB, Torri V, Porcu L, Donington J, Bestvina CM, Vokes E, Dolezal JM, Esposito A, Garassino MC. What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer? Ther Adv Med Oncol. 2023; 15:17588359231198446. PMID: 37720499; PMCID: PMC10504845.
      Citations:    
    12. Mazieres J, Paik PK, Le X, Veillon R, Cortot AB, Raskin J, Wu YL, Yang JCH, Ahn MJ, Ma R, Zhao J, O'Brate A, Berghoff K, Bruns R, Otto G, Johne A, Felip E, Thomas M, Garassino MC, Sakai H, Smit EF, Viteri S. Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2023 09 01; 9(9):1260-1266. PMID: 37270698; PMCID: PMC10240398.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    13. Garassino MC, Oskar S, Arunachalam A, Zu K, Kao YH, Chen C, Meng W, Pietanza MC, Zhao B, Aggarwal H. Real-World Treatment Patterns and Outcomes of First-Line Immunotherapy Among Patients With Advanced Nonsquamous NSCLC Harboring BRAF, MET, or HER2 Alterations. JTO Clin Res Rep. 2023 Oct; 4(10):100568. PMID: 37744307; PMCID: PMC10514206.
      Citations:    
    14. Brambilla M, Beninato T, Piemontese A, Mazzeo L, Pircher CC, Manglaviti S, Ambrosini P, Signorelli D, Lorenzini D, Prelaj A, Ferrara R, Proto C, Lo Russo G, Pizzutilo EG, Ganzinelli M, Grande I, Capone I, Di Mauro RM, Conca E, Dumitrascu AD, Zanella C, Leporati R, Rota S, Garassino MC, Marchetti P, Occhipinti M, de Braud FM. Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations. Clin Lung Cancer. 2023 11; 24(7):631-640.e2. PMID: 37775370.
      Citations:    Fields:    Translation:Humans
    15. Özgüroglu M, Kilickap S, Sezer A, Gümüs M, Bondarenko I, Gogishvili M, Nechaeva M, Schenker M, Cicin I, Ho GF, Kulyaba Y, Zyuhal K, Scheusan RI, Garassino MC, He X, Kaul M, Okoye E, Li Y, Li S, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023 09; 24(9):989-1001. PMID: 37591293.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    16. Aldea M, Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov. 2023 07 07; 13(7):1556-1571. PMID: 37068173.
      Citations: 10     Fields:    Translation:Humans
    17. Bestvina CM, Garassino MC, Neal JW, Wakelee HA, Diehn M, Vokes EE. Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal. J Clin Oncol. 2023 09 01; 41(25):4093-4096. PMID: 37352477.
      Citations: 1     Fields:    Translation:Humans
    18. Oliveri S, Lanzoni L, Veldwijk J, de Wit GA, Petrocchi S, Janssens R, Schoefs E, Smith MY, Smith I, Nackaerts K, Vandevelde M, Louis E, Decaluwé H, De Leyn P, Declerck H, Petrella F, Casiraghi M, Galli G, Garassino MC, Girvalaki C, Huys I, Pravettoni G. Balancing benefits and risks in lung cancer therapies: patient preferences for lung cancer treatment alternatives. Front Psychol. 2023; 14:1062830. PMID: 37425173; PMCID: PMC10325723.
      Citations:    
    19. Lo Russo G, Prelaj A, Dolezal J, Beninato T, Agnelli L, Triulzi T, Fabbri A, Lorenzini D, Ferrara R, Brambilla M, Occhipinti M, Mazzeo L, Provenzano L, Spagnoletti A, Viscardi G, Sgambelluri F, Brich S, Miskovic V, Pedrocchi ALG, Trovo' F, Manglaviti S, Giani C, Ambrosini P, Leporati R, Franza A, McCulloch J, Torelli T, Anichini A, Mortarini R, Trinchieri G, Pruneri G, Torri V, De Braud F, Proto C, Ganzinelli M, Garassino MC, Prelaj A. PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis. J Immunother Cancer. 2023 06; 11(6). PMID: 37286305; PMCID: PMC10254948.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    20. Dolezal JM, Wolk R, Hieromnimon HM, Howard FM, Srisuwananukorn A, Karpeyev D, Ramesh S, Kochanny S, Kwon JW, Agni M, Simon RC, Desai C, Kherallah R, Nguyen TD, Schulte JJ, Cole K, Khramtsova G, Garassino MC, Husain AN, Li H, Grossman R, Cipriani NA, Pearson AT. Deep learning generates synthetic cancer histology for explainability and education. NPJ Precis Oncol. 2023 May 29; 7(1):49. PMID: 37248379; PMCID: PMC10227067.
      Citations: 2     
    21. Hines JB, Bowar B, Levine E, Esposito A, Garassino MC, Bestvina CM. Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer. Int J Mol Sci. 2023 May 29; 24(11). PMID: 37298380; PMCID: PMC10253830.
      Citations: 2     Fields:    Translation:Humans
    22. Proto C, Manglaviti S, Lo Russo G, Musca M, Galli G, Imbimbo M, Perrino M, Cordua N, Rulli E, Ballatore Z, Maso AD, Chella A, Sbrana A, Prelaj A, Ferrara R, Occhipinti M, Brambilla M, De Toma A, Mazzeo L, Beninato T, Signorelli D, Massa G, Greco FG, Calareso G, Miliziano D, Di Mauro RM, Mella G, Lucarelli A, Paggio A, Galli F, Torri V, de Braud FGM, Pasello G, Petrini I, Berardi R, Ganzinelli M, Garassino MC, Zucali PA. STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines. J Thorac Oncol. 2023 08; 18(8):1070-1081. PMID: 37094664.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    23. Girard N, Garassino MC, Solomon B. Response to Letter to the Editor From Binghao Zhao et al. J Thorac Oncol. 2023 04; 18(4):e40-e41. PMID: 36990577.
      Citations:    Fields:    
    24. Cornelissen R, Prelaj A, Sun S, Baik C, Wollner M, Haura EB, Mamdani H, Riess JW, Cappuzzo F, Garassino MC, Heymach JV, Socinski MA, Leu SY, Bhat G, Lebel F, Le X, ZENITH20-4 Investigators. Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4). J Thorac Oncol. 2023 08; 18(8):1031-1041. PMID: 36958688.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    25. Prelaj A, Ganzinelli M, Trovo' F, Roisman LC, Pedrocchi ALG, Kosta S, Restelli M, Ambrosini E, Broggini M, Pravettoni G, Monzani D, Nuara A, Amat R, Spathas N, Willis M, Pearson A, Dolezal J, Mazzeo L, Sangaletti S, Correa AM, Aguaron A, Popa C, Raimondi G, Triulzi T, Steurer S, Lo Russo G, Linardou H, Peled N, Felip E, Garassino MC, Watermann I, Reck M. The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy. Clin Lung Cancer. 2023 06; 24(4):381-387. PMID: 36959048.
      Citations: 1     Fields:    Translation:Humans
    26. Linardou H, Adjei AA, Bajpai J, Banerjee S, Berghoff AS, Mathias CC, Choo SP, Dent R, Felip E, Furness AJS, Garassino MC, Garralda E, Konsoulova-Kirova A, Letsch A, Menzies AM, Mukherji D, Peters S, Sessa C, Tsang J, Yang JC, Garrido P. Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey. ESMO Open. 2023 04; 8(2):100781. PMID: 36842299; PMCID: PMC10163010.
      Citations: 1     Translation:Humans
    27. Garassino MC, Gadgeel S, Felip E, Esteban E, Hochmair MJ, Powell SF, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Kurata T, Gray JE, Schwarzenberger P, Jensen E, Pietanza MC, Speranza G, Dómine M, Rodríguez-Abreu D. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol. 2023 04 10; 41(11):1992-1998. PMID: 36809080; PMCID: PMC10082311.
      Citations: 35     Fields:    Translation:Humans
    28. Tran MC, Strohbehn GW, Karrison TG, Rouhani SJ, Segal JP, Shergill A, Hoffman PC, Patel JD, Garassino MC, Vokes EE, Bestvina CM. Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression. Clin Lung Cancer. 2023 05; 24(3):e117-e121. PMID: 36806414.
      Citations: 1     Fields:    Translation:Humans
    29. Prelaj A, Galli EG, Miskovic V, Pesenti M, Viscardi G, Pedica B, Mazzeo L, Bottiglieri A, Provenzano L, Spagnoletti A, Marinacci R, De Toma A, Proto C, Ferrara R, Brambilla M, Occhipinti M, Manglaviti S, Galli G, Signorelli D, Giani C, Beninato T, Pircher CC, Rametta A, Kosta S, Zanitti M, Di Mauro MR, Rinaldi A, Di Gregorio S, Antonia M, Garassino MC, de Braud FGM, Restelli M, Lo Russo G, Ganzinelli M, Pedrocchi ALG, Trovò F. Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients. Front Oncol. 2022; 12:1078822. PMID: 36755856; PMCID: PMC9899835.
      Citations: 2     
    30. Garassino MC, Faivre-Finn C. To the Editor. J Thorac Oncol. 2023 01; 18(1):e2-e3. PMID: 36543436.
      Citations:    Fields:    
    31. Lo Russo G, Sgambelluri F, Prelaj A, Galli F, Manglaviti S, Bottiglieri A, Di Mauro RM, Ferrara R, Galli G, Signorelli D, De Toma A, Occhipinti M, Brambilla M, Rulli E, Triulzi T, Torelli T, Agnelli L, Brich S, Martinetti A, Dumitrascu AD, Torri V, Pruneri G, Fabbri A, de Braud F, Anichini A, Proto C, Ganzinelli M, Mortarini R, Garassino MC. PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers. ESMO Open. 2022 Nov 28; 7(6):100645. PMID: 36455507.
      Citations: 3     
    32. Garassino MC, Gadgeel S, Novello S, Halmos B, Felip E, Hui R, Garon EB, Horinouchi H, Sugawara S, Rodriguez-Abreu D, Reck M, Cristescu R, Aurora-Garg D, Loboda A, Lunceford J, Kobie J, Ayers M, Piperdi B, Pietanza MC, Paz-Ares L, Speranza G. Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC. JTO Clin Res Rep. 2023 Jan; 4(1):100431. PMID: 36793385; PMCID: PMC9923193.
      Citations: 7     
    33. Dolezal JM, Srisuwananukorn A, Karpeyev D, Ramesh S, Kochanny S, Cody B, Mansfield AS, Rakshit S, Bansal R, Bois MC, Bungum AO, Schulte JJ, Vokes EE, Garassino MC, Husain AN, Pearson AT. Uncertainty-informed deep learning models enable high-confidence predictions for digital histopathology. Nat Commun. 2022 11 02; 13(1):6572. PMID: 36323656; PMCID: PMC9630455.
      Citations: 7     Fields:    Translation:Humans
    34. Girard N, Bar J, Garassino MC, McDonald F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Haakensen VD, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B, Garrido P, Mornex F, Sibille A, Fietkau R, Chouaid C. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study. J Thorac Oncol. 2023 02; 18(2):181-193. PMID: 36307040.
      Citations: 27     Fields:    Translation:Humans
    35. Tralongo AC, Massari F, Lambertini M, Mollica V, Rizzo A, Comito F, Di Liello R, Alfieri S, Imbimbo M, Lo Russo G, Proto C, Prelaj A, De Toma A, Galli G, Signorelli D, Chaput N, de Braud F, Garassino MC, Torri V, Cinquini M, Ferrara R, Viscardi G, Della Corte CM, Morgillo F, Simeon V, Ciardiello F, Remon J, Besse B. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. Eur J Cancer. 2022 Dec; 177:175-185. PMID: 36368251.
      Citations: 71     Fields:    Translation:Humans
    36. Signorelli D, Ghidotti P, Proto C, Brambilla M, De Toma A, Ferrara R, Galli G, Ganzinelli M, Lo Russo G, Prelaj A, Occhipinti M, Viscardi G, Capizzuto V, Pontis F, Petraroia I, Ferretti AM, Colombo MP, Torri V, Sozzi G, Garassino MC, Jachetti E, Fortunato O. Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC. Front Immunol. 2022; 13:987639. PMID: 36203609; PMCID: PMC9530186.
      Citations: 2     Fields:    Translation:HumansCells
    37. Rezania K, Soliven B, Garassino MC, Donington J. Postoperative Complications of Thymectomy in Myasthenia Gravis: Does Steroid Use Play a Role? Ann Thorac Surg. 2023 06; 115(6):1558. PMID: 36007565.
      Citations:    Fields:    Translation:Humans
    38. Garassino MC, Reck M, Bischoff H, Cove-Smith L, Mansy T, Cortinovis D, Migliorino MR, Delmonte A, Chara Velarde LE, Bernabe R, Paz-Ares L, Perez ID, Trunova N, Foroutanpour K, Faivre-Finn C, Mazieres J, Chouaid C, Reinmuth N, Sánchez JG. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial. J Thorac Oncol. 2022 12; 17(12):1415-1427. PMID: 35961520.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    39. Caglevic C, Rolfo C, Gil-Bazo I, Sapunar J, Hirsch FR, Gandara DR, Novello S, Garassino MC, Mountzios G, Leighl NB, Bretel D, Arrieta O, Addeo A, Liu SV, Subbiah V, Villarroel-Espindola F, Reyes-Cosmelli F, Morales R, Mahave M, Raez L, Santos E, Ubillos L, Tan DSW, Zielinski C, Cardona A, Morgan G, Corrales L, Aboitiz F, Alatorre J. The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations. JCO Glob Oncol. 2022 08; 8:e2200123. PMID: 35994695; PMCID: PMC9470147.
      Citations: 10     Fields:    Translation:Humans
    40. Galli G, Corsetto PA, Proto C, Lo Russo G, Ganzinelli M, Rulli E, Legramandi L, Morelli D, Ferrara R, Prelaj A, Signorelli D, De Toma A, Brambilla M, Occhipinti M, Manglaviti S, Boeri M, Martinetti A, Vingiani A, Colombo MP, Rizzo AM, Torri V, de Braud F, Sangaletti S, Sica A, Garassino MC. Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer. Clin Lung Cancer. 2022 Nov; 23(7):e489-e499. PMID: 35948460.
      Citations: 1     Fields:    Translation:Humans
    41. Campochiaro C, Farina N, Tomelleri A, Ferrara R, Viola S, Lazzari C, De Luca G, Raggi D, Bulotta A, Matucci-Cerinic M, Necchi A, Garassino M, Gregorc V, Dagna L. Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors. Eur J Intern Med. 2022 09; 103:95-99. PMID: 35821192.
      Citations: 4     Fields:    Translation:Humans
    42. Reck M, Mok TSK, Mansfield A, De Boer R, Losonczy G, Sugawara S, Dziadziuszko R, Krzakowski M, Smolin A, Hochmair M, Garassino MC, Lam S, Cardona A, Morris S, Liu SV, de Castro Junior G, Bischoff H. Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide. J Thorac Oncol. 2022 09; 17(9):1122-1129. PMID: 35764236.
      Citations: 6     Fields:    Translation:Humans
    43. Zattarin E, Manglaviti S, Apollonio G, Beninato T, Mazzeo L, Massa G, Bottiglieri A, Galli E, De Toma A, Occhipinti M, Brambilla M, Ferrara R, Ganzinelli M, Proto C, Garassino MC, de Braud F, Lo Russo G, Prelaj A. Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy. Future Oncol. 2022 Jul; 18(23):2593-2604. PMID: 35722877.
      Citations: 1     Fields:    Translation:HumansCells
    44. Piccirillo MC, Bonanno L, Garassino MC, Esposito G, Dazzi C, Cavanna L, Burgio MA, Rosetti F, Rizzato S, Cinieri S, Veccia A, Papi M, Tonini G, Ricciardi S, Pozzessere D, Ferro A, Proto C, Costanzo R, D'Arcangelo M, Proietto M, Gargiulo P, Di Liello R, Arenare L, De Marinis F, Normanno N, Perrone F, Gridelli C, Morabito A, Morgillo F, Gebbia V, Crinò L, Ciardiello F, Gallo C. Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial. J Thorac Oncol. 2022 09; 17(9):1086-1097. PMID: 35659580.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    45. Johnson M, Garassino MC, Mok T, Mitsudomi T. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies. Lung Cancer. 2022 08; 170:41-51. PMID: 35714425.
      Citations: 23     Fields:    Translation:Humans
    46. Bestvina CM, Whisenant JG, Torri V, Cortellini A, Wakelee H, Peters S, Roca E, De Toma A, Hirsch FR, Mamdani H, Halmos B, Arrieta O, Metivier AC, Fidler MJ, Rogado J, Presley CJ, Mascaux C, Genova C, Blaquier JB, Addeo A, Finocchiaro G, Khan H, Morgillo F, Bar J, Aujayeb A, Mountzios G, Scotti V, Grosso F, Geraedts E, Zhumagaliyeva AN, Horn L, Garassino MC, Baena J, TERAVOLT study group, Mazieres J. Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis. JTO Clin Res Rep. 2022 Aug; 3(8):100335. PMID: 35619644; PMCID: PMC9119707.
      Citations: 8     
    47. Chen Y, Paz-Ares L, Reinmuth N, Garassino MC, Statsenko G, Hochmair MJ, Verderame F, Havel L, Conev NV, Hotta K, Ji JH, Spencer S, Dalvi T, Jiang H, Goldman JW, Özgüroglu M, Losonczy G. Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report. JTO Clin Res Rep. 2022 Jun; 3(6):100330. PMID: 35719865; PMCID: PMC9204731.
      Citations: 9     
    48. Le X, Sakai H, Felip E, Veillon R, Garassino MC, Raskin J, Cortot AB, Mazieres J, Smit EF, Thomas M, Iams WT, Cho BC, Kim HR, Yang JC, Chen YM, Patel JD, Bestvina CM, Park K, Griesinger F, Johnson M, Gottfried M, Britschgi C, Heymach J, Sikoglu E, Berghoff K, Schumacher KM, Bruns R, Otto G, Paik PK, Viteri S. Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. Clin Cancer Res. 2022 03 15; 28(6):1117-1126. PMID: 34789481; PMCID: PMC9365370.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    49. Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Musso E, Havel L, Bondarenko I, Losonczy G, Conev N, Mann H, Dalvi TB, Jiang H, Goldman JW, Özgüroglu M. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022 04; 7(2):100408. PMID: 35279527; PMCID: PMC9161394.
      Citations: 53     Translation:Humans
    50. Ferrara R, Milani M, Garassino MC, Colombo MP, Sangaletti S. Adenosine Pathway in NSCLC With Molecular Drivers: Can Oncogene Addiction Translate Into Immune Addiction? J Thorac Oncol. 2022 03; 17(3):e35-e38. PMID: 35216738.
      Citations:    Fields:    Translation:Humans
    51. Giugliano F, Zucali PA, Galli G, Corti C, Aliaga PT, Uliano J, Vivanet G, Curigliano G, Conforti F, Queirolo P, Manglaviti S, Apollonio G, Perrino M, Borea F, D'Antonio F, Garassino MC, De Pas T, Ballatore Z, Berardi R. SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis. Eur J Cancer. 2022 05; 166:202-207. PMID: 35306318; PMCID: PMC8872961.
      Citations: 3     Fields:    Translation:HumansCells
    52. Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R, Quantin X, Rimner A, Wu YL, Lee KH, Kato T, Kurata T, Reck M, Cho BC, Senan S, Naidoo J, Mann H, Newton M, Thiyagarajah P, Antonia SJ, Özgüroglu M, de Wit M. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 04 20; 40(12):1301-1311. PMID: 35108059; PMCID: PMC9015199.
      Citations: 180     Fields:    Translation:Humans
    53. Whisenant JG, Baena J, Cortellini A, Huang LC, Lo Russo G, Porcu L, Wong SK, Bestvina CM, Hellmann MD, Roca E, Rizvi H, Rogado J, Pasello G, Leighl NB, Aujayeb A, Batra U, Azzam AY, Unk M, Azab MA, Zhumagaliyeva AN, Gomez-Martin C, Geraedts E, Mountzios G, Serrano-Montero G, Reinmuth N, Coate L, Marmarelis M, Presley CJ, Hirsch FR, Khan H, Baggi A, Halmos B, Ceresoli GL, Fidler MJ, Scotti V, Felip E, Tapan U, Brahmer J, Puri S, Popat S, Reckamp KL, Nadal E, Mazzoni F, Agustoni F, Bar J, Grosso F, Patel JD, Gomes F, Ibrahim E, Trama A, Bettini AC, Dingemans AM, Wakelee H, Peters S, Horn L, Garassino MC, Torri V, TERAVOLT study group, Monnet I, Boudjemaa A, Arrieta O, Blaquier JB, Garrido P, Mascaux C, Métivier AC, Falchero L, Genova C, Mazieres J, Bria E, Morgillo F, Avrillon V, Barlesi F. A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. J Thorac Oncol. 2022 05; 17(5):661-674. PMID: 35121086; PMCID: PMC8804493.
      Citations: 5     Fields:    Translation:HumansCells
    54. Prelaj A, Boeri M, Robuschi A, Ferrara R, Proto C, Lo Russo G, Galli G, De Toma A, Brambilla M, Occhipinti M, Manglaviti S, Beninato T, Bottiglieri A, Massa G, Zattarin E, Gallucci R, Galli EG, Ganzinelli M, Sozzi G, de Braud FGM, Garassino MC, Restelli M, Pedrocchi ALG, Trovo' F. Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy. Cancers (Basel). 2022 Jan 16; 14(2). PMID: 35053597; PMCID: PMC8773718.
      Citations: 7     
    55. Desai A, Mohammed TJ, Duma N, Garassino MC, Hicks LK, Kuderer NM, Lyman GH, Mishra S, Pinato DJ, Rini BI, Peters S, Warner JL, Whisenant JG, Wood WA, Thompson MA. COVID-19 and Cancer: A Review of the Registry-Based Pandemic Response. JAMA Oncol. 2021 12 01; 7(12):1882-1890. PMID: 34473192; PMCID: PMC8805603.
      Citations: 24     Fields:    Translation:HumansPHPublic Health
    56. Le X, Cornelissen R, Garassino M, Clarke JM, Tchekmedyian N, Goldman JW, Leu SY, Bhat G, Lebel F, Heymach JV, Socinski MA. Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. J Clin Oncol. 2022 03 01; 40(7):710-718. PMID: 34843401; PMCID: PMC8887939.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    57. Vernieri C, Ligorio F, Huber V, Vingiani A, Iannelli F, Raimondi A, Rinchai D, Belfiore A, Lalli L, Chiodoni C, Cancila V, Zanardi F, Ajazi A, Cortellino S, Vallacchi V, Squarcina P, Cova A, Pesce S, Frati P, Mall R, Corsetto PA, Rizzo AM, Ferraris C, Folli S, Garassino MC, Capri G, Bianchi G, Colombo MP, Minucci S, Foiani M, Longo VD, Apolone G, Torri V, Pruneri G, Bedognetti D, Rivoltini L, de Braud F, Fucà G, Frigè G. Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. Cancer Discov. 2022 01; 12(1):90-107. PMID: 34789537.
      Citations: 57     Fields:    Translation:HumansCTClinical Trials
    58. Filippi AR, Garassino M, Shirvani SM, Feldman J, Higgins KA. Comprehensive metastatic ablation in advanced NSCLC through biology-guided radiotherapy - A path forward? Lung Cancer. 2021 12; 162:203-206. PMID: 34742582.
      Citations:    Fields:    Translation:Humans
    59. Berghoff AS, Sessa C, Yang JC, Tsourti Z, Tsang J, Tabernero J, Peters S, Linardou H, Letsch A, Haanen J, Garralda E, Garassino MC, Furness AJS, Felip E, Dimopoulou G, Dafni U, Choo SP, Banerjee S, Bajpai J, Adjei AA, Garrido P. Female leadership in oncology-has progress stalled? Data from the ESMO W4O authorship and monitoring studies. ESMO Open. 2021 12; 6(6):100281. PMID: 34924143; PMCID: PMC8710465.
      Citations: 5     Translation:Humans
    60. Pinto C, Zucali PA, Pagano M, Grosso F, Pasello G, Garassino MC, Tiseo M, Soto Parra H, Cappuzzo F, de Marinis F, Pedrazzoli P, Bonomi M, Gianoncelli L, Perrino M, Santoro A, Zanelli F, Bonelli C, Maconi A, Frega S, Gervasi E, Boni L, Ceresoli GL, Grossi F. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2021 10; 22(10):1438-1447. PMID: 34499874.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    61. Campochiaro C, Farina N, Tomelleri A, Ferrara R, Lazzari C, De Luca G, Bulotta A, Signorelli D, Palmisano A, Vignale D, Peretto G, Sala S, Esposito A, Garassino M, Gregorc V, Dagna L. Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. Eur J Intern Med. 2021 11; 93:87-94. PMID: 34391591.
      Citations: 22     Fields:    Translation:Humans
    62. Monzani D, Petrocchi S, Oliveri S, Veldwijk J, Janssens R, Bailo L, Smith MY, Smith I, Schoefs E, Nackaerts K, Vandevelde M, Louis E, De Leyn P, Declerck H, Katz EG, Petrella F, Casiraghi M, Durosini I, Galli G, Garassino MC, de Wit GA, Pravettoni G, Huys I, Decaluwé H. Patient Preferences for Lung Cancer Treatments: A Study Protocol for a Preference Survey Using Discrete Choice Experiment and Swing Weighting. Front Med (Lausanne). 2021; 8:689114. PMID: 34409049; PMCID: PMC8365300.
      Citations: 4     
    63. Lindsay CR, Garassino MC, Nadal E, Scheffler M, Öhrling K, Mazières J. On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma. Lung Cancer. 2021 10; 160:152-165. PMID: 34417059.
      Citations: 10     Fields:    Translation:Humans
    64. Powell SF, Langer CJ, Tafreshi A, Paz-Ares L, Kowalski DM, Cheng Y, Kurata T, Awad MM, Lin J, Zhao B, Pietanza MC, Piperdi B, Garassino MC, Rodríguez-Abreu D, Kopp HG, Rodríguez-Cid J. Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407. J Thorac Oncol. 2021 11; 16(11):1883-1892. PMID: 34265431.
      Citations: 68     Fields:    Translation:Humans
    65. Manglaviti S, Brambilla M, Signorelli D, Ferrara R, Lo Russo G, Proto C, Galli G, De Toma A, Occhipinti M, Beninato T, Zattarin E, Bini M, Lobefaro R, Massa G, Bottiglieri A, Apollonio G, Sottotetti E, Di Mauro RM, Trevisan B, Ganzinelli M, Fabbri A, de Braud FGM, Garassino MC, Prelaj A, Viscardi G. Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology. Clin Lung Cancer. 2022 01; 23(1):e17-e28. PMID: 34334296.
      Citations: 8     Fields:    Translation:Humans
    66. Conforti F, Marino M, Vitolo V, Mantegazza R, Zucali P, Ruffini E, di Tommaso L, Pelosi G, Barberis M, Petrini I, Palmieri G, Pasello G, Galli G, Garassino M, Filosso P, Alloisio M, Scorsetti M, Orecchia R, Pala L, Abatedaga L, Cinieri S, De Pas T, Spaggiari L, Berardi R. Clinical management of patients with thymic epithelial tumors: the recommendations endorsed by the Italian Association of Medical Oncology (AIOM). ESMO Open. 2021 08; 6(4):100188. PMID: 34116501; PMCID: PMC8193108.
      Citations: 4     Translation:Humans
    67. Reck M, Carbone DP, Garassino M, Barlesi F. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021 09; 32(9):1101-1110. PMID: 34089836.
      Citations: 80     Fields:    Translation:Humans
    68. Ferrara R, Signorelli D, Proto C, Prelaj A, Garassino MC, Lo Russo G. Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations. Transl Lung Cancer Res. 2021 Jun; 10(6):2955-2969. PMID: 34295690; PMCID: PMC8264338.
      Citations: 1     
    69. Adjei AA, Bajpai J, Banerjee S, Berghoff AS, Choo SP, Felip E, Furness AJS, Garralda E, Haanen J, Letsch A, Linardou H, Peters S, Sessa C, Tabernero J, Tsang J, Yang JC, Garassino MC, Garrido P. Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey. ESMO Open. 2021 06; 6(3):100131. PMID: 34144778; PMCID: PMC8233649.
      Citations: 7     Translation:HumansCellsPHPublic Health
    70. Popat S, Brustugun OT, Felip E, Garassino MC, Bent-Ennakhil N, Kruhl C, Novello S, Cadranel J, Griesinger F, Helland Å, Hochmair M, Pérol M. Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. Lung Cancer. 2021 07; 157:9-16. PMID: 34051652.
      Citations: 4     Fields:    Translation:Humans
    71. Occhipinti M, Brambilla M, Galli G, Manglaviti S, Giammaruco M, Prelaj A, Ferrara R, De Toma A, Proto C, Beninato T, Zattarin E, Lo Russo G, Gelibter AJ, Simmaco M, Garassino MC, De Braud F, Marchetti P, Preissner R. Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors. J Pers Med. 2021 May 18; 11(5). PMID: 34069851; PMCID: PMC8157378.
      Citations: 2     
    72. Buti S, Bersanelli M, Perrone F, Bracarda S, Di Maio M, Giusti R, Nigro O, Cortinovis DL, Aerts JGJV, Guaitoli G, Barbieri F, Grossi F, Bareggi C, Sforza V, Genova C, Chiari R, Rocco D, Della Gravara L, Gori S, Di Marino P, Mansueto G, Zoratto F, Filetti M, Citarella F, Russano M, Mazzoni F, Garassino MC, De Toma A, Signorelli D, Gelibter A, Siringo M, Follador A, Bisonni R, Tuzi A, Minuti G, Landi L, Ricciardi S, Migliorino MR, Olmetto E, Metro G, Adamo V, Russo A, Spinelli GP, Banna GL, Addeo A, Friedlaender A, Cannita K, Porzio G, Ficorella C, Carmisciano L, Mazzaschi G, Tiseo M, Cortellini A, Ferrara MG, Bria E, Berardi R, Torniai M, Cantini L, De Tursi M, Tabbò F, Pinato DJ. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. Eur J Cancer. 2021 06; 150:224-231. PMID: 33934059.
      Citations: 15     Fields:    Translation:Humans
    73. Powell SF, Hochmair MJ, Gadgeel S, Esteban E, Felip E, Cheng SY, Bischoff HG, Peled N, Reck M, Hui R, Garon EB, Boyer M, Kurata T, Yang J, Pietanza MC, Souza F, Garassino MC, Rodríguez-Abreu D, Speranza G, De Angelis F, Dómine M. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021 07; 32(7):881-895. PMID: 33894335.
      Citations: 119     Fields:    Translation:Humans
    74. Stachowicz-Stencel T, Synakiewicz A, Ferrari A, Garassino M, Masip JR, Julien R, Virgone C, Schneider DT, Brecht IB, Ben-Ami T, Bien E, Godzinski J, Bisogno G, Orbach D, Cornet M, Reguerre Y, Sarnacki S. Thymoma and thymic carcinoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. Pediatr Blood Cancer. 2021 06; 68 Suppl 4:e29042. PMID: 33881200.
      Citations: 2     Fields:    Translation:Humans
    75. Borzi C, Ganzinelli M, Caiola E, Colombo M, Centonze G, Boeri M, Signorelli D, Caleca L, Rulli E, Busico A, Capone I, Pastorino U, Marabese M, Milione M, Broggini M, Garassino MC, Sozzi G, Moro M. LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress-Based Treatments. J Thorac Oncol. 2021 08; 16(8):1298-1311. PMID: 33887464.
      Citations: 6     Fields:    Translation:HumansCells
    76. Park K, Vansteenkiste J, Spigel D, Yang JCH, Ishii H, Garassino M, de Marinis F, Szczesna A, Polychronis A, Uslu R, Krzakowski M, Lee JS, Xiong H, Bajars M, Ruisi M, Barlesi F, Özgüroglu M, Calabrò L, Arén Frontera O. Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. J Thorac Oncol. 2021 08; 16(8):1369-1378. PMID: 33845211.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    77. Sangaletti S, Ferrara R, Tripodo C, Garassino MC, Colombo MP. Myeloid cell heterogeneity in lung cancer: implication for immunotherapy. Cancer Immunol Immunother. 2021 Sep; 70(9):2429-2438. PMID: 33797567; PMCID: PMC8017108.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    78. Prelaj A, Bottiglieri A, Proto C, Lo Russo G, Signorelli D, Ferrara R, Galli G, De Toma A, Viscardi G, Brambilla M, Lobefaro R, Nichetti F, Manglaviti S, Occhipinti M, Labianca A, Ganzinelli M, Gallucci R, Zilembo N, Greco GF, Torri V, de Braud F, Garassino MC. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program. Eur J Cancer. 2021 05; 149:235-248. PMID: 33820681.
      Citations: 26     Fields:    Translation:Humans
    79. Cortellini A, Di Maio M, Nigro O, Leonetti A, Cortinovis DL, Aerts JG, Guaitoli G, Barbieri F, Giusti R, Ferrara MG, Bria E, D'Argento E, Grossi F, Rijavec E, Guida A, Sforza V, Genova C, Mazzoni F, Garassino MC, De Toma A, Signorelli D, Gelibter A, Siringo M, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Della Gravara L, Inno A, Di Marino P, Mansueto G, Zoratto F, Filetti M, Santini D, Citarella F, Russano M, Cantini L, Tuzi A, Bordi P, Minuti G, Landi L, Ricciardi S, Migliorino MR, Passiglia F, Bironzo P, Metro G, Spinelli GP, Banna GL, Friedlaender A, Addeo A, Cannita K, Ficorella C, Porzio G, Pinato DJ, Berardi R, Torniai M, Michele T, Grassadonia A, Adamo V, Russo A. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. J Immunother Cancer. 2021 04; 9(4). PMID: 33827906; PMCID: PMC8031700.
      Citations: 52     Fields:    Translation:Humans
    80. Punie K, Personeni N, Ferrara R, Pels K, Garassino M, Lopes G, Barlesi F, Choueiri TK, Burris H, Morgan G, de Azambuja E, Ades F, Heinrich K, Rahme R, von Bergwelt-Baildon M, Peters S. OncoAlert Round Table Discussions: The Global COVID-19 Experience. JCO Glob Oncol. 2021 04; 7:455-463. PMID: 33822643; PMCID: PMC8221235.
      Citations: 2     Fields:    Translation:HumansCellsPHPublic Health
    81. Scarfone G, Fumagalli M, Imbimbo M, Ceruti T, Di Loreto E, D'Incalci M, Facchin F, Fontana C, Garassino MC, Peccatori FA, Persico N, Signorelli D, Zucchetti M, Cribiù FM. First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report. J Thorac Oncol. 2021 05; 16(5):873-877. PMID: 33795207.
      Citations: 7     Fields:    Translation:Humans
    82. Petrelli F, Ghidini A, Roudi R, Sabet MN, Facelli S, Luciani A, Roviello G, Ferrara R, Signorelli D, Proto C, Garassino MC. Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis. Immunotherapy. 2021 05; 13(7):621-631. PMID: 33775103.
      Citations: 23     Fields:    Translation:Humans
    83. De Toma A, Lo Russo G, Signorelli D, Pagani F, Randon G, Galli G, Prelaj A, Ferrara R, Proto C, Ganzinelli M, Zilembo N, de Braud F, Garassino MC. Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. Crit Rev Oncol Hematol. 2021 Apr; 160:103299. PMID: 33722699.
      Citations: 2     Fields:    Translation:Humans
    84. Prelaj A, Pircher CC, Massa G, Martelli V, Corrao G, Lo Russo G, Proto C, Ferrara R, Galli G, De Toma A, Genova C, Jereczek-Fossa BA, Braud F, Garassino MC, Rebuzzi SE. Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression. Cancers (Basel). 2021 Mar 15; 13(6). PMID: 33803958; PMCID: PMC7999258.
      Citations: 8     
    85. Daveri E, Luison E, Vallacchi V, Vergani B, Leone BE, Garassino MC, Figini M, Rivoltini L. Is impaired response to PD-1 blockers of high serum PD-1 patients related to immune complexes? Ann Oncol. 2021 06; 32(6):814-816. PMID: 33684461.
      Citations: 1     Fields:    Translation:Humans
    86. Passaro A, Bestvina C, Velez Velez M, Garassino MC, Garon E, Peters S. Severity of COVID-19 in patients with lung cancer: evidence and challenges. J Immunother Cancer. 2021 03; 9(3). PMID: 33737345; PMCID: PMC7978268.
      Citations: 49     Fields:    Translation:HumansCells
    87. Garon EB, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, Natale R, Schneider J, Shepherd FA, Garassino MC, Geater SL, Szekely ZP, Van Ngoc T, Liu F, Scheuring U, Patel N, Peters S, Rizvi NA, Robinet G, Le Moulec S. Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC). Clin Lung Cancer. 2021 07; 22(4):301-312.e8. PMID: 33775558.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    88. Garassino MC, Paz-Ares L, Hui R, Faivre-Finn C, Planchard D, Vicente D, Murakami S, Senan S, O'Brien C, Spira A, Özgüroglu M, Daniel D, Langer C, Spigel D, Rydén A, Zhang Y, Dennis PA, Antonia SJ. Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. Future Oncol. 2021 Apr; 17(10):1165-1184. PMID: 33583206.
      Citations: 1     Fields:    Translation:Humans
    89. Garassino MC, Vyas M, de Vries EGE, Kanesvaran R, Giuliani R, Peters S, European Society for Medical Oncology. The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate. Ann Oncol. 2021 05; 32(5):579-581. PMID: 33582237; PMCID: PMC7879154.
      Citations: 45     Fields:    Translation:HumansCellsPHPublic Health
    90. Durosini I, Janssens R, Arnou R, Veldwijk J, Smith MY, Monzani D, Smith I, Galli G, Garassino M, Katz EG, Bailo L, Louis E, Vandevelde M, Nackaerts K, de Wit GA, Pravettoni G, Huys I. Patient Preferences for Lung Cancer Treatment: A Qualitative Study Protocol Among Advanced Lung Cancer Patients. Front Public Health. 2021; 9:622154. PMID: 33634069; PMCID: PMC7900128.
      Citations: 7     Fields:    Translation:Humans
    91. Horgan D, Ciliberto G, Conte P, Curigliano G, Montuenga LM, Garassino M, Galli F, Riegman P, Kerr K, Van Poppel H, Bjartell A, Codacci-Pisanelli G, Koeva-Balabanova J, Paradiso A, Maravic Z, Fotaki V, Bernini C, Buglioni S, Kent A, Munzone E, Belina I, Van Meerbeeck J, Duffy M, Jagielska B, Capoluongo E, Seijo L, Penault-Llorca F, Ray-Coquard I, Querleu D, Malats N. Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine. Cancers (Basel). 2021 Feb 02; 13(3). PMID: 33540773; PMCID: PMC7867284.
      Citations: 6     
    92. Ferrara R, Campochiaro C, Garassino MC. Shifting From a "One Size Fits All" to a Tailored Approach for Immune-Related Adverse Events. J Thorac Oncol. 2021 02; 16(2):183-186. PMID: 33494923.
      Citations: 2     Fields:    Translation:Humans
    93. Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste JF, Spigel DR, Garassino MC, Reck M, Senan S, Naidoo J, Rimner A, Wu YL, Gray JE, Lee KH, Cho BC, Kato T, Newton M, Wang L, Thiyagarajah P, Antonia SJ, Özgüroglu M, de Wit M. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. J Thorac Oncol. 2021 05; 16(5):860-867. PMID: 33476803.
      Citations: 184     Fields:    Translation:HumansCTClinical Trials
    94. Garassino MC, Ribas A. At the Crossroads: COVID-19 and Immune-Checkpoint Blockade for Cancer. Cancer Immunol Res. 2021 03; 9(3):261-264. PMID: 33452008; PMCID: PMC8052929.
      Citations: 14     Fields:    Translation:HumansCellsPHPublic Health
    95. Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, Pluzanski A, Chiari R, Butts C, Garassino MC, Ready N, Felip E, Waterhouse D, Domine M, Barlesi F, Antonia S, Wohlleber M, Gerber DE, Spigel DR, Crino L, Eberhardt WEE, Li A, Marimuthu S, Brahmer J, Arrieta O, Frontera OA, Wójcik-Tomaszewska J, Coudert B, García MA, Czyzewicz G. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol. 2021 03 01; 39(7):723-733. PMID: 33449799; PMCID: PMC8078445.
      Citations: 190     Fields:    Translation:Humans
    96. Cona MS, Cecere FL, Chiari R, Guarneri V, La Verde N, Locati L, Lorusso D, Giannarelli D, Garassino MC, Women for Oncology Italy, Berardi R, Torniai M, Martinelli E. Social distress among medical oncologists and other healthcare professionals during the first wave of COVID-19 pandemic in Italy. ESMO Open. 2021 04; 6(2):100053. PMID: 33601297; PMCID: PMC7900700.
      Citations: 8     Translation:Humans
    97. Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, Garassino MC, De Castro Carpeno J, Califano R, Nishio M, Alatorre-Alexander J, Leal T, Cheng Y, Lee JS, Lam S, McCleland M, Deng Y, Phan S, Horn L, Orlandi F. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021 02 20; 39(6):619-630. PMID: 33439693; PMCID: PMC8078320.
      Citations: 189     Fields:    Translation:HumansCTClinical Trials
    98. Ganzinelli M, Linardou H, Alvisi MF, Caiola E, Lo Russo G, Cecere FL, Bettini AC, Psyrri A, Milella M, Rulli E, Fabbri A, De Maglie M, Romanelli P, Murray S, Broggini M, Marabese M, Garassino MC. Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy. ESMO Open. 2021 02; 6(1):100034. PMID: 33422766; PMCID: PMC7809372.
      Citations:    Translation:Humans
    99. Horn L, Garassino M. COVID-19 in patients with cancer: managing a pandemic within a pandemic. Nat Rev Clin Oncol. 2021 01; 18(1):1-2. PMID: 33060841; PMCID: PMC7557307.
      Citations: 14     Fields:    Translation:HumansCellsPHPublic Health
    100. Lobefaro R, Massa G, Ferrara R, Signorelli D, Proto C, Prelaj A, Galli G, De Toma A, Brambilla M, Ganzinelli M, Trevisan B, De Braud F, Garassino MC, Lo Russo G, Viscardi G, Di Liello R, Iacovino ML, Sparano F, Della Corte CM, Ciardiello F, Morgillo F. Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. Lung Cancer. 2021 02; 152:165-173. PMID: 33421923.
      Citations: 16     Fields:    Translation:Humans
    101. Brambilla M, Russo GL, Ferrara R, Manglaviti S, Garassino MC, Occhipinti M. Is hyperprogressive disease a specific phenomenom of immunotherapy? Explor Target Antitumor Ther. 2020; 1(6):427-433. PMID: 36046388; PMCID: PMC9402399.
      Citations: 1     
    102. Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L, CASPIAN investigators, Özgüroglu M, Losonczy G. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021 01; 22(1):51-65. PMID: 33285097.
      Citations: 197     Fields:    Translation:HumansCTClinical Trials
    103. Antonangeli F, Natalini A, Garassino MC, Sica A, Santoni A, Di Rosa F. Regulation of PD-L1 Expression by NF-?B in Cancer. Front Immunol. 2020; 11:584626. PMID: 33324403; PMCID: PMC7724774.
      Citations: 102     Fields:    Translation:HumansCells
    104. Borzi C, Galli G, Ganzinelli M, Signorelli D, Vernieri C, Garassino MC, Sozzi G, Moro M. Beyond LKB1 Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment. Pharmaceuticals (Basel). 2020 Nov 13; 13(11). PMID: 33202760; PMCID: PMC7697441.
      Citations: 2     
    105. Gurizzan C, Roca E, Cortinovis D, Signorelli D, Pagani F, Bettini A, Bonomi L, Rinaldi S, Berardi R, Filetti M, Giusti R, Intagliata S, Baggi A, Cortellini A, Soto Parra H, Brighenti M, Petrelli F, Bennati C, Bidoli P, Garassino MC, Berruti A, Laganà M, Pilotto S, Milella M. High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases. Front Oncol. 2020; 10:588862. PMID: 33282740; PMCID: PMC7689017.
      Citations: 7     
    106. Bianchi F, Garassino MC, Tagliabue E, Camelliti S, Le Noci V, Moscheni C, Arnaboldi F, Gagliano N, Balsari A, Sfondrini L, Sommariva M. Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know. J Exp Clin Cancer Res. 2020 Nov 09; 39(1):236. PMID: 33168050; PMCID: PMC7650183.
      Citations: 26     Fields:    Translation:Humans
    107. Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Lefebvre C, Veillon R, Koscielny S, Champiat S, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Lo Russo G, Signorelli D, Garassino MC, Soria JC, Caramella C, Besse B, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Westeel V, Ferté C. Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy. JCO Precis Oncol. 2020 Nov; 4:829-840. PMID: 35050757.
      Citations: 9     Fields:    
    108. Bersanelli M, Buti S, Giannarelli D, Leonetti A, Cortellini A, Russo GL, Signorelli D, Toschi L, Milella M, Pilotto S, Proto C, Marinello A, Randon G, Rossi S, Sartori G, Qako E, Giaiacopi E, Ghilardi L, Bettini AC, Rapacchi E, Mazzoni F, Lavacchi D, Scotti V, Ciccone LP, Bordi P, Di Maio M, Audisio M, Filetti M, Giusti R, Cerea G, Pizzutilo EG, Bearz A, De Carlo E, Cecere F, Renna D, Camisa R, Caruso G, Ficorella C, Banna GL, Cortinovis D, Brighenti M, Garassino MC, Tiseo M, Bria E, Vita E, D'Argento E, De Tursi M, Di Marino P, Santini D, Russano M, Berardi R, Fiordoliva I. Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. Lung Cancer. 2020 12; 150:123-131. PMID: 33130353.
      Citations: 7     Fields:    Translation:Humans
    109. Marton G, Vergani L, Mazzocco K, Garassino MC, Pravettoni G. 2020s Heroes Are Not Fearless: The Impact of the COVID-19 Pandemic on Wellbeing and Emotions of Italian Health Care Workers During Italy Phase 1. Front Psychol. 2020; 11:588762. PMID: 33178088; PMCID: PMC7593839.
      Citations: 20     
    110. Mountzios G, de Toma A, Economopoulou P, Friedlaender A, Banini M, Lo Russo G, Baxevanos P, Roila F, Banna GL, Christopoulou A, Jimenez B, Collazo-Lorduy A, Linardou H, Galetta D, Addeo A, Camerini A, Pizzutilo P, Kosmidis P, Garassino MC, Proto C, Signorelli D, Metro G, Calles A. Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy. Clin Lung Cancer. 2021 03; 22(2):e180-e192. PMID: 33162330.
      Citations: 8     Fields:    Translation:Humans
    111. Ceresoli LG, Zucali PA, Pasello G, Garassino M, Grosso F, Tiseo M, Soto Parra H, Cappuzzo F, Grossi F, De Marinis F, Pedrazzoli P, Normanno N, Pagano M, Zanelli F, Gnoni R, Bonelli C, Torricelli F, Ciarrocchi A, Pinto C. Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study. Cancers (Basel). 2020 Oct 13; 12(10). PMID: 33065998; PMCID: PMC7601196.
      Citations: 10     
    112. Trama A, Proto C, Whisenant JG, Torri V, Cortellini A, Michielin O, Barlesi F, Dingemans AC, Van Meerbeeck J, Mazieres J, Soo RA, Leighl NB, Peters S, Wakelee H, Horn L, Hellmann M, Wong SK, Garassino MC, Baena J, Pancaldi V. Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience. Cancer Cell. 2020 11 09; 38(5):602-604. PMID: 33091381; PMCID: PMC7534826.
      Citations: 3     Fields:    Translation:HumansCellsPHPublic Health
    113. Signorelli D, Proto C, Botta L, Trama A, Tiseo M, Pasello G, Lo Russo G, Fabbri A, Imbimbo M, Busico A, Prelaj A, Ferrara R, Galli G, De Toma A, Tamborini E, Pastorino U, de Braud F, Gatta G, Garassino MC, Ganzinelli M. SMO mutations confer poor prognosis in malignant pleural mesothelioma. Transl Lung Cancer Res. 2020 Oct; 9(5):1940-1951. PMID: 33209614; PMCID: PMC7653142.
      Citations: 1     
    114. Garassino MC, Besse B, Torri V. To Continue or Not to Continue? That Is the Question. J Clin Oncol. 2020 11 20; 38(33):3830-3832. PMID: 32997574.
      Citations: 1     Fields:    Translation:Humans
    115. Horgan D, Ciliberto G, Conte P, Baldwin D, Seijo L, Montuenga LM, Paz-Ares L, Garassino M, Penault-Llorca F, Galli F, Banerjee S, Riegman P, Kerr K, Horbach B, Van Poppel H, Codacci-Pisanelli G, Westphalen B, Calvo F, Koeva-Balabanova J, Hall S, Paradiso A, Kalra D, Cobbaert C, Varea Menendez R, Maravic Z, Fotaki V, Bennouna J, Cauchin E, Malats N, Gannon B, Mastris K, Bernini C, Gallagher W, Buglioni S, Kent A, Munzone E, Belina I, Van Meerbeeck J, Duffy M, Sarnowska E, Jagielska B, Mee S, Curigliano G, Ray-Coquard I, Querleu D, Capoluongo E, Büttner R, Bjartell A, Gutiérrez-Ibarluzea I. Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology. Biomed Hub. 2020 Sep-Dec; 5(3):182-223. PMID: 33564664; PMCID: PMC7841733.
      Citations: 8     
    116. Borghaei H, Langer CJ, Paz-Ares L, Halmos B, Garassino MC, Houghton B, Kurata T, Cheng Y, Lin J, Pietanza MC, Piperdi B, Gadgeel SM, Rodríguez-Abreu D. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Cancer. 2020 11 15; 126(22):4867-4877. PMID: 32914866; PMCID: PMC7692929.
      Citations: 40     Fields:    Translation:Humans
    117. Goldman JW, Garassino MC, Chen Y, Dvorkin M, Trukhin D, Statsenko G, Hotta K, Ji JH, Hochmair MJ, Voitko O, Havel L, Poltoratskiy A, Reinmuth N, Patel N, Laud PJ, Shire N, Jiang H, Paz-Ares L, Özgüroglu M, Losonczy G. Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. Lung Cancer. 2020 11; 149:46-52. PMID: 32961445.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    118. Ferrara R, Naigeon M, Duchemann B, Cassard L, Jouniaux JM, Boselli L, Grivel J, Desnoyer A, Mezquita L, Texier M, Caramella C, Hendriks L, Planchard D, Remon J, Sangaletti S, Proto C, Garassino MC, Soria JC, Besse B, Chaput N, Auclin E, Marabelle A, Voisin AL, Farhane S. Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. Clin Cancer Res. 2021 01 15; 27(2):492-503. PMID: 32887723.
      Citations: 47     Fields:    Translation:HumansCells
    119. Banna GL, Signorelli D, Metro G, Galetta D, De Toma A, Cantale O, Banini M, Friedlaender A, Pizzutillo P, Garassino MC, Addeo A. Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab. Transl Lung Cancer Res. 2020 Aug; 9(4):1533-1542. PMID: 32953525; PMCID: PMC7481583.
      Citations: 27     
    120. Curigliano G, Banerjee S, Cervantes A, Garassino MC, Haanen J, Jordan K, Lordick F, Michielin O, Peters S, Tabernero J, Pentheroudakis G, Panel members, Garrido P, Girard N, Machiels JP, Douillard JY. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol. 2020 10; 31(10):1320-1335. PMID: 32745693; PMCID: PMC7836806.
      Citations: 138     Fields:    Translation:HumansCellsPHPublic Health
    121. Alvisi MF, Ganzinelli M, Linardou H, Caiola E, Lo Russo G, Cecere FL, Bettini AC, Psyrri A, Milella M, Rulli E, Fabbri A, De Maglie M, Romanelli P, Murray S, Ndembe G, Broggini M, Garassino MC, Marabese M. Predicting the Role of DNA Polymerase ß Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy. J Clin Med. 2020 Jul 30; 9(8). PMID: 32751518; PMCID: PMC7465625.
      Citations: 1     
    122. Sica A, Colombo MP, Trama A, Horn L, Garassino MC, Torri V. Immunometabolic Status of COVID-19 Cancer Patients. Physiol Rev. 2020 10 01; 100(4):1839-1850. PMID: 32721181; PMCID: PMC7839651.
      Citations: 13     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    123. Gelsomino F, Lamberti G, Tiseo M, Rocco D, Pasello G, Cecere FL, Chella A, Grilli G, Mandruzzato M, Tognetto M, Garassino MC, Macerelli M, Novello S, Roila F, Colantonio I, Grossi F, Fiorentino M, Ardizzoni A. Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial). Ther Adv Med Oncol. 2020; 12:1758835920915983. PMID: 32733604; PMCID: PMC7372524.
      Citations: 4     
    124. Melis E, Gallo E, di Martino S, Gallina FT, Laquintana V, Casini B, Visca P, Ganci F, Alessandrini G, Caterino M, Cecere FL, Mandoj C, Papadantonakis A, De Bello N, Lattanzio R, Palmieri G, Garassino MC, Girard N, Conti L, Blandino G, Fazi F, Facciolo F, Pescarmona E, Ciliberto G, Marino M. Thymic Epithelial Tumors as a Model of Networking: Development of a Synergistic Strategy for Clinical and Translational Research Purposes. Front Oncol. 2020; 10:922. PMID: 32760665; PMCID: PMC7372300.
      Citations: 1     
    125. Garassino MC, Cho BC, Kim JH, Vansteenkiste J, Jaime JC, Gray JE, Powderly J, Bidoli P, Wheatley-Price P, Park K, Soo RA, Poole L, Wadsworth C, Dennis PA, Rizvi NA, Mazières J, Lena H, Chouaid C. Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study. Lung Cancer. 2020 09; 147:137-142. PMID: 32702570.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    126. Nichetti F, Lo Russo G, Prelaj A, Provenzano L, de Braud F, Cabiddu M, Garassino MC, Petrelli F. ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients? Thromb Res. 2020 10; 194:176-177. PMID: 32788112.
      Citations: 2     Fields:    Translation:Humans
    127. Friedlaender A, Metro G, Signorelli D, Gili A, Economopoulou P, Roila F, Banna G, De Toma A, Camerini A, Christopoulou A, Lo Russo G, Banini M, Galetta D, Jimenez B, Collazo-Lorduy A, Baxevanos P, Linardou H, Kosmidis P, Mountzios G, Garassino MC, Addeo A, Calles A. Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score =50% treated with front-line pembrolizumab. Acta Oncol. 2020 Sep; 59(9):1058-1063. PMID: 32762415.
      Citations: 17     Fields:    Translation:Humans
    128. Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, Baena J, Banna G, Bettini AC, Brighenti M, Cadranel J, De Toma A, Chini C, Cortellini A, Felip E, Finocchiaro G, Genova C, Giusti R, Gregorc V, Grossi F, Grosso F, Intagliata S, La Verde N, Liu SV, Mazieres J, Mercadante E, Michielin O, Minuti G, Moro-Sibilot D, Pasello G, Passaro A, Scotti V, Solli P, Stroppa E, Tiseo M, Viscardi G, Voltolini L, Wu YL, Zai S, Dingemans AM, Van Meerbeeck J, Barlesi F, Wakelee H, Peters S, Horn L, TERAVOLT investigators, Berardi R, Bria E, Garrido P, Pancaldi V. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020 07; 21(7):914-922. PMID: 32539942; PMCID: PMC7292610.
      Citations: 337     Fields:    Translation:HumansCellsPHPublic Health
    129. Prelaj A, Proto C, Lo Russo G, Signorelli D, Ferrara R, Mensah M, Galli G, De Toma A, Viscardi G, Brambilla M, Lobefaro R, Trevisan B, Torri V, Sozzi G, Garassino MC, Boeri M, Trovò F. Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system. Transl Lung Cancer Res. 2020 Jun; 9(3):617-628. PMID: 32676324; PMCID: PMC7354114.
      Citations: 3     
    130. Pietrantonio F, Garassino MC. Caring for Patients With Cancer During the COVID-19 Outbreak in Italy. JAMA Oncol. 2020 06 01; 6(6):821-822. PMID: 32275294.
      Citations: 24     Fields:    Translation:HumansCellsPHPublic Health
    131. Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 09 03; 383(10):931-943. PMID: 32469185; PMCID: PMC8422679.
      Citations: 271     Fields:    Translation:HumansCTClinical Trials
    132. Galli G, Trama A, Abate-Daga L, Brambilla M, Garassino MC, Fabbri A. Accuracy of pathologic diagnosis for thymic epithelial tumors: a brief report from an Italian reference Center. Lung Cancer. 2020 08; 146:66-69. PMID: 32516667.
      Citations: 1     Fields:    Translation:Humans
    133. Whisenant JG, Trama A, Torri V, De Toma A, Viscardi G, Cortellini A, Michielin O, Barlesi F, Dingemans AC, Van Meerbeeck J, Soo RA, Leighl NB, Peters S, Wakelee H, Garassino MC, Horn L, Pancaldi V. TERAVOLT: Thoracic Cancers International COVID-19 Collaboration. Cancer Cell. 2020 06 08; 37(6):742-745. PMID: 32425702; PMCID: PMC7229923.
      Citations: 33     Fields:    Translation:HumansCellsPHPublic Health
    134. Dingemans AC, Soo RA, Jazieh AR, Rice SJ, Kim YT, Teo LLS, Warren GW, Xiao SY, Smit EF, Aerts JG, Yoon SH, Veronesi G, De Cobelli F, Ramalingam SS, Garassino MC, Wynes MW, Behera M, Haanen J, Lu S, Peters S, Ahn MJ, Scagliotti GV, Adjei AA, Belani CP. Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic. J Thorac Oncol. 2020 07; 15(7):1119-1136. PMID: 32422364; PMCID: PMC7227539.
      Citations: 55     Fields:    Translation:HumansCellsPHPublic Health
    135. Trama A, Proto C, Signorelli D, Garassino MC, Lo Russo G, Ganzinelli M, Prelaj A, Mensi C, Gangemi M, Gennaro V, Chellini E, Caldarella A, Angelillo IF, Ascoli V, Pascucci C, Tagliabue G, Cusimano R, Bella F, Merler E, Masanotti G, Ziino A, Michiara M, Gola G, Vitale MF, Cirilli C, Tumino R, Scuderi T, Fanetti AC, Piffer S, Tiseo M, Gatta G, Botta L, LUME study WG, Falcini F, Storchi C, Mangone L. Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study. Thorac Cancer. 2020 06; 11(6):1661-1669. PMID: 32364316; PMCID: PMC7262944.
      Citations:    Fields:    Translation:Humans
    136. Vernieri C, Ganzinelli M, Rulli E, Farina G, Bettini AC, Bareggi C, Rosso L, Signorelli D, Galli G, Lo Russo G, Proto C, Moro M, Indraccolo S, Busico A, Sozzi G, Torri V, Marabese M, Massimo B, Garassino MC. LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. ESMO Open. 2020 05; 5(3):e000748. PMID: 32467099; PMCID: PMC7259832.
      Citations: 1     Translation:Humans
    137. Lo Russo G, Facchinetti F, Tiseo M, Garassino MC, Ferrara R. Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer. Curr Oncol Rep. 2020 04 16; 22(5):41. PMID: 32296957.
      Citations: 14     Fields:    Translation:Humans
    138. Mazzaschi G, Barbieri F, Passiglia F, Mazzoni F, Proto C, Cecere FL, Pilotto S, Scotti V, Rossi S, Del Conte A, Bennati C, Ardizzoni A, Cerea G, Migliorino MR, Sala E, Camerini A, Bearz A, De Carlo E, Guaitoli G, Garassino MC, Ciccone LP, Sartori G, Toschi L, Dall'Olio FG, Landi L, Bartoli G, Baldessari C, Novello S, Cortinovis DL, Rossi G, Rossi A, Banna GL, Camisa R, Di Maio M, Tiseo M, Facchinetti F, Berardi R, Vita E, Zanelli F, Pizzutilo EG, Bria E. First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. Eur J Cancer. 2020 05; 130:155-167. PMID: 32220780.
      Citations: 52     Fields:    Translation:Humans
    139. Gadgeel S, Esteban E, Felip E, Hui R, Hochmair MJ, Clingan P, Powell SF, Cheng SY, Bischoff HG, Peled N, Jennens RR, Reck M, Garon EB, Novello S, Boyer M, Kurata T, Gray JE, Yang J, Bas T, Pietanza MC, Garassino MC, Rodríguez-Abreu D, Speranza G, Dómine M, Grossi F, Rubio-Viqueira B. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020 05 10; 38(14):1505-1517. PMID: 32150489.
      Citations: 382     Fields:    Translation:Humans
    140. Babacan NA, Pina IB, Signorelli D, Prelaj A, Garassino MC, Tanvetyanon T. Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis. Clin Lung Cancer. 2020 09; 21(5):e456-e463. PMID: 32265109.
      Citations: 19     Fields:    Translation:Humans
    141. Prelaj A, Lo Russo G, Proto C, Signorelli D, Ferrara R, Galli G, De Toma A, Randon G, Pagani F, Trevisan B, Ganzinelli M, Zilembo N, Montrone M, Longo V, Pesola F, Pizzutilo P, Del Bene G, Galetta D, Torri V, Garassino MC, Di Maio M, Catino A, Varesano N. DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation. Clin Lung Cancer. 2020 09; 21(5):e337-e348. PMID: 32291212.
      Citations: 2     Fields:    Translation:Humans
    142. Petrelli F, Signorelli D, Ghidini M, Ghidini A, Pizzutilo EG, Ruggieri L, Cabiddu M, Borgonovo K, Dognini G, Brighenti M, De Toma A, Rijavec E, Garassino MC, Grossi F, Tomasello G. Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Cancers (Basel). 2020 Feb 27; 12(3). PMID: 32120803; PMCID: PMC7139305.
      Citations: 111     
    143. Corrao G, Marvaso G, Ferrara R, Lo Russo G, Gugliandolo SG, Piperno G, Spaggiari L, De Marinis F, Orecchia R, Garassino MC, Jereczek-Fossa BA. Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases. Lung Cancer. 2020 04; 142:70-79. PMID: 32120227.
      Citations: 7     Fields:    Translation:Humans
    144. Beninato T, Lo Russo G, Garassino MC, De Braud F, Platania M. Recurrent thrombosis followed by Lazarus response in ROS1 rearranged NSCLC treated with crizotinib: a case report. Tumori. 2020 Dec; 106(6):NP41-NP45. PMID: 32066344.
      Citations: 3     Fields:    Translation:Humans
    145. Garassino MC, Gadgeel S, Esteban E, Felip E, Hochmair MJ, Powell S, Cheng SY, Bischoff HG, Peled N, Reck M, Hui R, Garon EB, Boyer M, Wei Z, Burke T, Pietanza MC, Speranza G, Domine M, Rodríguez-Abreu D. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 03; 21(3):387-397. PMID: 32035514.
      Citations: 74     Fields:    Translation:HumansCTClinical Trials
    146. Nichetti F, Ligorio F, Zattarin E, Signorelli D, Prelaj A, Proto C, Galli G, Marra A, Apollonio G, Porcu L, de Braud F, Lo Russo G, Ferrara R, Garassino MC. Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients. Cancers (Basel). 2019 Dec 25; 12(1). PMID: 31881699; PMCID: PMC7016680.
      Citations: 25     
    147. Mansfield AS, Kazarnowicz A, Karaseva N, De Boer R, Andric Z, Atagi S, Lee JS, Garassino M, Liu SV, Horn L, Wen X, Quach C, Yu W, Kabbinavar F, Lam S, Morris S, Califano R, Sánchez A, Reck M. Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial. Ann Oncol. 2020 02; 31(2):310-317. PMID: 31959349.
      Citations: 60     Fields:    Translation:HumansCTClinical Trials
    148. Prelaj A, Ferrara R, Rebuzzi SE, Proto C, Signorelli D, Galli G, De Toma A, Randon G, Pagani F, Viscardi G, Brambilla M, Trevisan B, Ganzinelli M, Martinetti A, Gallucci R, Di Mauro RM, Molino G, Zilembo N, Torri V, de Braud FM, Garassino MC, Lo Russo G. EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort. Cancers (Basel). 2019 12 05; 11(12). PMID: 31817541; PMCID: PMC6966664.
      Citations: 34     
    149. Metro G, Addeo A, Signorelli D, Gili A, Economopoulou P, Roila F, Banna G, De Toma A, Rey Cobo J, Camerini A, Christopoulou A, Lo Russo G, Banini M, Galetta D, Jimenez B, Collazo-Lorduy A, Baxevanos P, Linardou H, Kosmidis P, Garassino MC, Mountzios G, Calles A. Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 =50% who progress on first-line immunotherapy: real-world data from a European cohort. J Thorac Dis. 2019 Dec; 11(12):4972-4981. PMID: 32030213; PMCID: PMC6988053.
      Citations: 15     
    150. Caiola E, Iezzi A, Tomanelli M, Bonaldi E, Scagliotti A, Colombo M, Guffanti F, Micotti E, Garassino MC, Minoli L, Scanziani E, Broggini M, Marabese M. LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors. J Thorac Oncol. 2020 03; 15(3):360-370. PMID: 31634668.
      Citations: 16     Fields:    Translation:Humans
    151. Del Re M, Petrini I, Mazzoni F, Valleggi S, Gianfilippo G, Pozzessere D, Chella A, Crucitta S, Rofi E, Restante G, Miccoli M, Garassino MC, Danesi R. Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. Clin Lung Cancer. 2020 05; 21(3):232-237. PMID: 31735523.
      Citations: 14     Fields:    Translation:Humans
    152. Caraceni A, Lo Dico S, Zecca E, Brunelli C, Bracchi P, Mariani L, Garassino MC, Vitali M. Outpatient palliative care and thoracic medical oncology: Referral criteria and clinical care pathways. Lung Cancer. 2020 01; 139:13-17. PMID: 31704278.
      Citations: 3     Fields:    Translation:Humans
    153. Romeo MAL, Garassino MC, Moiola L, Galli G, Comi G, Martinelli V, Filippi M. Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer. J Neurol. 2019 12; 266(12):3163-3166. PMID: 31586260.
      Citations: 2     Fields:    Translation:Humans
    154. Galli G, De Toma A, Pagani F, Randon G, Trevisan B, Prelaj A, Ferrara R, Proto C, Signorelli D, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G. Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. Lung Cancer. 2019 11; 137:38-42. PMID: 31526910.
      Citations: 28     Fields:    Translation:Humans
    155. Galli G, Proto C, Cossa M, Valeri B, Sdao S, Signorelli D, Imbimbo M, de Braud F, Garassino MC, Lo Russo G. Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer. Tumori. 2019 Dec; 105(6):NP57-NP62. PMID: 31456503.
      Citations: 1     Fields:    Translation:Humans
    156. Antonia SJ, Borghaei H, Ramalingam SS, Horn L, Pluzanski A, Burgio MA, Garassino M, Chow LQM, Gettinger S, Planchard D, Butts C, Drilon A, Wojcik-Tomaszewska J, Otterson GA, Agrawal S, Li A, Penrod JR, Brahmer J, De Castro Carpeño J, Crinò L. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol. 2019 10; 20(10):1395-1408. PMID: 31422028; PMCID: PMC7193685.
      Citations: 128     Fields:    Translation:Humans
    157. Galli G, Proto C, Signorelli D, Imbimbo M, Ferrara R, Prelaj A, De Toma A, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G. Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. Future Oncol. 2019 Aug; 15(23):2743-2757. PMID: 31339060.
      Citations: 4     Fields:    Translation:Humans
    158. Proto C, Signorelli D, Prelaj A, Lo Russo G, Imbimbo M, Galli G, Ferrara R, Ganzinelli M, Leuzzi G, Greco FG, Calareso G, Botta L, Gatta G, Garassino M, Trama A, Mallone S. The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma. Clin Lung Cancer. 2019 11; 20(6):e652-e660. PMID: 31377142.
      Citations: 3     Fields:    Translation:Humans
    159. Garassino MC, Sica A, Bleve A. Membrane Cholesterol Regulates Macrophage Plasticity in Cancer. Cell Metab. 2019 06 04; 29(6):1238-1240. PMID: 31167119.
      Citations: 9     Fields:    Translation:HumansCells
    160. Boothman AM, Scott M, Ratcliffe M, Whiteley J, Dennis PA, Wadsworth C, Sharpe A, Rizvi NA, Garassino MC, Walker J. Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study. J Thorac Oncol. 2019 08; 14(8):1390-1399. PMID: 31063864.
      Citations: 16     Fields:    Translation:Humans
    161. Galli G, Triulzi T, Proto C, Signorelli D, Imbimbo M, Poggi M, Ganzinelli M, Vitali M, Palmieri D, Tessari A, Garassino MC, Colombo MP, Lo Russo G, Fucà G, de Braud F. Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. Lung Cancer. 2019 06; 132:72-78. PMID: 31097097.
      Citations: 30     Fields:    Translation:Humans
    162. Platania M, Pasini F, Porcu L, Boeri M, Verderame F, Modena Y, Del Conte A, Nichetti F, Garassino MC, Martinetti A, Sottotetti E, Cavanna L, Vattemi E, Pozzessere D, Bertolini A, Irtelli L, Verri C, Sozzi G, Proto C, Pastorino U, Torri V, Fraccon AP, Spinnato F, Signorelli D, Lo Russo G, Tuzi A, Gallucci R, Cinieri S, Mencoboni M, Antonelli P, Giacomelli L, de Braud F. Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. Lung Cancer. 2019 06; 132:17-23. PMID: 31097088.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    163. Proto C, Ferrara R, Signorelli D, Lo Russo G, Galli G, Imbimbo M, Prelaj A, Zilembo N, Ganzinelli M, Pallavicini LM, De Simone I, Colombo MP, Sica A, Torri V, Garassino MC. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. Cancer Treat Rev. 2019 May; 75:39-51. PMID: 30954906.
      Citations: 68     Fields:    Translation:Humans
    164. Rihawi K, Giannarelli D, Galetta D, Delmonte A, Giavarra M, Turci D, Garassino M, Tiseo M, Barbieri F, Panni S, Ardizzoni A. BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience. J Thorac Oncol. 2019 03; 14(3):e57-e59. PMID: 30782386.
      Citations: 19     Fields:    Translation:Humans
    165. Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M, Ferrara R, Zilembo N, Ganzinelli M, Torri V, Colombo MP, Vernieri C, Balsari A, de Braud F, Garassino MC, Signorelli D, Fucà G, Sica A. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open. 2019; 4(1):e000457. PMID: 30964126; PMCID: PMC6435242.
      Citations: 86     
    166. Ciani O, Cucciniello M, Petracca F, Apolone G, Merlini G, Novello S, Pedrazzoli P, Zilembo N, Broglia C, Capelletto E, Garassino M, Nicod E, Tarricone R. Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer. BMJ Open. 2019 02 15; 9(2):e025483. PMID: 30772862; PMCID: PMC6398637.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    167. Peters S, Dafni U, Boyer M, De Ruysscher D, Faivre-Finn C, Felip E, Girard N, Guckenberger M, Haanen J, Le Pechoux C, Ozsahin M, Paz-Ares L, Planchard D, Raben D, Ramalingam S, Reck M, Smit E, Stenzinger A, Swanton C, Vallone S, Garassino MC, Garrido P, Mornex F, Stahel R. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Ann Oncol. 2019 02 01; 30(2):161-165. PMID: 30624547.
      Citations: 22     Fields:    Translation:Humans
    168. Bronte G, Bidoli P, Cravero P, Minenza E, Cortesi E, Garassino MC, Proto C, Cappuzzo F, Grossi F, Tonini G, Sarobba MG, Pinotti G, Numico G, Samaritani R, Frassoldati A, Bregni M, Santo A, Piantedosi F, Illiano A, De Marinis F, Tamberi S, Giannarelli D, Delmonte A, Crinò L, Ciuffreda L. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer. 2019 03; 129:35-40. PMID: 30797489.
      Citations: 63     Fields:    Translation:Humans
    169. Levy BP, Giaccone G, Besse B, Felip E, Garassino MC, Piperdi B, Ponce-Aix S, Menezes D, MacBeth KJ, Slepetis R, Wu X, Fandi A, Paz-Ares L, Domine Gomez M, Garrido P, Risueño A. Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. Eur J Cancer. 2019 02; 108:120-128. PMID: 30654297.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    170. Boeri M, Milione M, Proto C, Signorelli D, Lo Russo G, Verri C, Mensah M, Centonze G, Martinetti A, Sottotetti E, Pastorino U, Garassino MC, Sozzi G, Galeone C. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. Clin Cancer Res. 2019 04 01; 25(7):2166-2173. PMID: 30617131; PMCID: PMC6445748.
      Citations: 40     Fields:    Translation:HumansCells
    171. Lo Russo G, Tessari A, Capece M, Galli G, de Braud F, Garassino MC, Palmieri D. MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review. Front Oncol. 2018; 8:650. PMID: 30622932; PMCID: PMC6308141.
      Citations: 25     
    172. Vernieri C, Signorelli D, Galli G, Ganzinelli M, Moro M, Fabbri A, Tamborini E, Marabese M, Caiola E, Broggini M, Hollander L, Gallucci R, Vandoni G, Gavazzi C, Triulzi T, Colombo MP, Pruneri G, de Braud F, Sozzi G, Torri V, Garassino MC, Rizzo AM, Corsetto PA. Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. Clin Lung Cancer. 2019 05; 20(3):e413-e417. PMID: 30617039.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    173. Caiola E, Falcetta F, Giordano S, Marabese M, Garassino MC, Broggini M, Pastorelli R, Brunelli L. Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach. J Exp Clin Cancer Res. 2018 Dec 04; 37(1):302. PMID: 30514331; PMCID: PMC6280460.
      Citations: 14     Fields:    Translation:HumansCells
    174. Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M, Vitali M, Ganzinelli M, Lanti C, Molino G, Stangoni F, Zilembo N, de Braud F, Garassino MC, Signorelli D, Fucà G. Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. Target Oncol. 2018 12; 13(6):795-800. PMID: 30306460.
      Citations: 9     Fields:    Translation:Humans
    175. Garassino MC, Kawaguchi T, Gregorc V, Rulli E, Ando M, Marsoni S, Isa SI, Novello S, Farina G, Barni S, Torri V, Cinquini M. Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: an individual patient data (IPD) analysis. ESMO Open. 2018; 3(6):e000327. PMID: 30555723; PMCID: PMC6267321.
      Citations: 2     
    176. Garassino MC, Catino A, Ardizzoni A, Cortesi E, Cappuzzo F, Bordi P, Barbieri F, Santo A, Altavilla G, Ambrosio F, Mini E, Vasile E, Scoppola A, Bengala C, Follador A, Tedde N, Giannarelli D, Lo Russo G, Vitiello F, Crinò L, Calabrò L, Morgillo F. Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program. Tumour Biol. 2018 Nov; 40(11):1010428318815047. PMID: 30486741.
      Citations: 1     Fields:    Translation:Humans
    177. Garassino MC, Torri V, Colombo MP, Sica A. Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity. Cancer Res. 2018 10 15; 78(20):5729-5730. PMID: 30322956.
      Citations: 6     Fields:    Translation:HumansCells
    178. Imbimbo M, Ottaviano M, Vitali M, Fabbri A, Leuzzi G, Fiore M, Franceschini D, Pasello G, Perrino M, Schiavon M, Pruneri G, Dei Tos AP, Sangalli C, Garassino MC, Alessi A, Calareso G, Petrini I, Scorsetti M, Scotti V, Rea F, Pastorino U, Casali PG, Ramella S, Ricardi U, Abate-Daga L, Torri V, Trama A, Palmieri G, Marino M, Zucali PA, TYME network collaborators, Berardi R, Rosso L. Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). Cancer Treat Rev. 2018 Dec; 71:76-87. PMID: 30366202.
      Citations: 22     Fields:    Translation:Humans
    179. Vansteenkiste J, Spigel D, Ishii H, Garassino M, de Marinis F, Szczesna A, Polychronis A, Uslu R, Krzakowski M, Lee JS, Ellers-Lenz B, Bajars M, Ruisi M, Park K, Barlesi F, Özgüroglu M, Calabrò L, Arén Frontera O. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol. 2018 11; 19(11):1468-1479. PMID: 30262187.
      Citations: 196     Fields:    Translation:HumansCTClinical Trials
    180. Dafni U, Allen T, Arnold D, Banerjee S, Curigliano G, Garralda E, Garassino MC, Haanen J, Robert C, Sessa C, Tsourti Z, Zygoura P, Peters S, Hofstädter-Thalmann E. Report on the status of women occupying leadership roles in oncology. ESMO Open. 2018; 3(6):e000423. PMID: 30273418; PMCID: PMC6157529.
      Citations: 21     
    181. Banerjee S, Dafni U, Allen T, Arnold D, Curigliano G, Garralda E, Garassino MC, Haanen J, Robert C, Sessa C, Tsourti Z, Zygoura P, Peters S, Hofstädter-Thalmann E. Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey. ESMO Open. 2018; 3(6):e000422. PMID: 30273420; PMCID: PMC6157518.
      Citations: 24     
    182. Gandhi L, Garassino MC. Pembrolizumab plus Chemotherapy in Lung Cancer. N Engl J Med. 2018 09 13; 379(11):e18. PMID: 30207917.
      Citations: 29     Fields:    Translation:Humans
    183. Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V, Milione M, Porcu L, Proto C, Pruneri G, Signorelli D, Sangaletti S, Sfondrini L, Storti C, Tassi E, Bardelli A, Marsoni S, Torri V, Tripodo C, Colombo MP, Anichini A, Rivoltini L, Balsari A, Sozzi G, Garassino MC. Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. Clin Cancer Res. 2019 02 01; 25(3):989-999. PMID: 30206165.
      Citations: 191     Fields:    Translation:HumansAnimalsCells
    184. Moro M, Caiola E, Ganzinelli M, Zulato E, Rulli E, Marabese M, Centonze G, Busico A, Pastorino U, de Braud FG, Vernieri C, Simbolo M, Scarpa A, Indraccolo S, Broggini M, Sozzi G, Garassino MC, Bria E. Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. J Thorac Oncol. 2018 11; 13(11):1692-1704. PMID: 30149143.
      Citations: 42     Fields:    Translation:Humans
    185. Tessari A, Parbhoo K, Pawlikowski M, Fassan M, Rulli E, Foray C, Fabbri A, Embrione V, Ganzinelli M, Capece M, Campbell MJ, Broggini M, La Perle K, Farina G, Cole S, Marabese M, Hernandez M, Amann JM, Pruneri G, Carbone DP, Garassino MC, Croce CM, Palmieri D, Coppola V. RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients. Oncogene. 2018 12; 37(50):6463-6476. PMID: 30076413; PMCID: PMC6690599.
      Citations: 9     Fields:    Translation:HumansAnimals
    186. Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, Hodge R, Kaur P, Brown AP, Ghiorghiu D, Papadimitrakopoulou VA, Mok TSK. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). J Clin Oncol. 2018 09 10; 36(26):2702-2709. PMID: 30059262.
      Citations: 199     Fields:    Translation:HumansCTClinical Trials
    187. Imbimbo M, Vitali M, Fabbri A, Ottaviano M, Pasello G, Petrini I, Palmieri G, Zucali P, Ganzinelli M, Marabese M, Broggini M, Marino M, Trama A, Rulli E, Hollander L, Pruneri G, Torri V, Garassino MC, Berardi R. RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma. Clin Lung Cancer. 2018 09; 19(5):e811-e814. PMID: 30033090.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    188. Garassino MC, Gelibter AJ, Grossi F, Chiari R, Soto Parra H, Cascinu S, Cognetti F, Turci D, Blasi L, Bengala C, Mini E, Baldini E, Quadrini S, Ceresoli GL, Antonelli P, Vasile E, Pinto C, Fasola G, Galetta D, Macerelli M, Giannarelli D, Lo Russo G, de Marinis F. Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. J Thorac Oncol. 2018 08; 13(8):1146-1155. PMID: 29730379.
      Citations: 41     Fields:    Translation:Humans
    189. KEYNOTE-189 Investigators, Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018 May 31; 378(22):2078-2092. PMID: 29658856.
      Citations: 2474     Fields:    Translation:HumansCTClinical Trials
    190. Vokes EE, Ready N, Felip E, Horn L, Burgio MA, Antonia SJ, Gettinger S, Holgado E, Spigel D, Waterhouse D, Garassino M, Chow LQM, Blumenschein G, Gainor J, Brahmer J, Butts C, Steins M, Geese WJ, Li A, Healey D, Arén Frontera O, Domine M, Barlesi F, Coudert B, Arrieta O, Crinò L. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018 04 01; 29(4):959-965. PMID: 29408986.
      Citations: 227     Fields:    Translation:Humans
    191. Reck M, Garassino MC, Imbimbo M, Shepherd FA, Socinski MA, Shih JY, Tsao A, Lee P, Winfree KB, Sashegyi A, Cheng R, Varea R, Levy B, Garon E. Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. Lung Cancer. 2018 06; 120:62-69. PMID: 29748017.
      Citations: 20     Fields:    Translation:HumansAnimals
    192. Lo Russo G, Corrao G, Galli G, Pusceddu S, Inno A, Salgarello M, Casolino R, Modena A, Romano L, Greco FG, Garassino MC, Gori S. The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST. Tumori. 2018 Mar-Apr; 104(2):88-95. PMID: 29714647.
      Citations: 11     Fields:    Translation:Humans
    193. Garassino MC, Cho BC, Kim JH, Vansteenkiste J, Corral Jaime J, Gray JE, Powderly J, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA, ATLANTIC Investigators, Mazières J, Lena H, Chouaid C. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018 04; 19(4):521-536. PMID: 29545095; PMCID: PMC7771363.
      Citations: 280     Fields:    Translation:HumansCTClinical Trials
    194. Grynovska M, Lucibello F, Tsao MS, Shepherd FA, Bouchaab H, Garassino M, Aerts JGJV, Costantini A, Moisés J, Pagès F, Mazières J, Mondini M, Berghmans T, Meert AP, Cadranel J. Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly. Eur Respir J. 2018 02; 51(2). PMID: 29444918.
      Citations: 8     Fields:    Translation:Humans
    195. Imbimbo M, Garassino M, RARECAREnet Working Group, Maury JM, Girard N. Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting. Eur J Surg Oncol. 2019 01; 45(1):75-80. PMID: 29426781.
      Citations: 8     Fields:    Translation:Humans
    196. Caiola E, Frapolli R, Tomanelli M, Valerio R, Iezzi A, Garassino MC, Broggini M, Marabese M. Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib. Sci Rep. 2018 01 17; 8(1):948. PMID: 29343688; PMCID: PMC5772438.
      Citations: 10     Fields:    Translation:HumansCells
    197. Facchinetti F, Proto C, Minari R, Garassino M, Tiseo M. Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer. Handb Exp Pharmacol. 2018; 249:63-89. PMID: 28332047.
      Citations: 7     Fields:    Translation:Humans
    198. Galli G, Corrao G, Imbimbo M, Proto C, Signorelli D, Ganzinelli M, Zilembo N, Vitali M, de Braud F, Garassino MC, Lo Russo G. Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review. Lung Cancer. 2018 01; 115:135-142. PMID: 29290256.
      Citations: 15     Fields:    Translation:Humans
    199. Vitali M, Ripamonti CI, Roila F, Proto C, Signorelli D, Imbimbo M, Corrao G, Brissa A, Rosaria G, de Braud F, Garassino MC, Lo Russo G. Cognitive impairment and chemotherapy: a brief overview. Crit Rev Oncol Hematol. 2017 Oct; 118:7-14. PMID: 28917271.
      Citations: 28     Fields:    Translation:Humans
    200. Proto C, Lo Russo G, Corrao G, Ganzinelli M, Facchinetti F, Minari R, Tiseo M, Garassino MC. Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms. Tumori. 2017 Jul 31; 103(4):325-337. PMID: 28708233.
      Citations: 6     Fields:    Translation:Humans
    201. Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, Toh CK, Rizvi NA, Chaft JE, Carcereny Costa E, Patel JD, Chow LQM, Koczywas M, Ho C, Früh M, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd FA, Kurata T, Li Z, Qiu J, Kowanetz M, Mocci S, Shankar G, Sandler A, Felip E. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol. 2017 Aug 20; 35(24):2781-2789. PMID: 28609226; PMCID: PMC5562171.
      Citations: 186     Fields:    Translation:HumansCTClinical Trials
    202. Lo Russo G, Imbimbo M, Corrao G, Proto C, Signorelli D, Vitali M, Ganzinelli M, Botta L, Zilembo N, de Braud F, Garassino MC. Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases. Oncotarget. 2017 Aug 29; 8(35):59889-59900. PMID: 28938691; PMCID: PMC5601787.
      Citations: 21     Fields:    
    203. Lo Russo G, Macerelli M, Platania M, Zilembo N, Vitali M, Signorelli D, Proto C, Ganzinelli M, Gallucci R, Agustoni F, Fasola G, de Braud F, Garassino MC. Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem. Curr Drug Targets. 2017; 18(3):341-362. PMID: 27138756.
      Citations: 7     Fields:    Translation:Humans
    204. Rulli E, Guffanti F, Caiola E, Ganzinelli M, Damia G, Garassino MC, Piva S, Ceppi L, Broggini M, Marabese M. The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs. Sci Rep. 2016 12 14; 6:39217. PMID: 27966655; PMCID: PMC5155271.
      Citations: 2     Fields:    Translation:Humans
    205. Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA, AURA3 Investigators. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017 02 16; 376(7):629-640. PMID: 27959700; PMCID: PMC6762027.
      Citations: 1338     Fields:    Translation:HumansCTClinical Trials
    206. Proto C, Imbimbo M, Gallucci R, Brissa A, Signorelli D, Vitali M, Macerelli M, Corrao G, Ganzinelli M, Greco FG, Garassino MC, Lo Russo G. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future. Transl Lung Cancer Res. 2016 Dec; 5(6):563-578. PMID: 28149752; PMCID: PMC5233868.
      Citations: 19     
    207. Califano R, Kerr K, Morgan RD, Lo Russo G, Garassino M, Morgillo F, Rossi A. Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. Curr Oncol Rep. 2016 09; 18(9):59. PMID: 27484062.
      Citations: 19     Fields:    Translation:Humans
    208. Peretti U, Ferrara R, Pilotto S, Kinspergher S, Caccese M, Santo A, Brunelli M, Carbognin L, Sperduti I, Garassino M, Chilosi M, Scarpa A, Tortora G, Bria E, Caliò A. ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations. Respir Res. 2016 08 25; 17(1):105. PMID: 27561692; PMCID: PMC5000438.
      Citations: 4     Fields:    Translation:Humans
    209. Lo Russo G, Pusceddu S, Prinzi N, Imbimbo M, Proto C, Signorelli D, Vitali M, Ganzinelli M, Maccauro M, Buzzoni R, Seregni E, de Braud F, Garassino MC. Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors. Tumour Biol. 2016 Oct; 37(10):12991-13003. PMID: 27460087.
      Citations: 9     Fields:    Translation:Humans
    210. Macerelli M, Ganzinelli M, Gouedard C, Broggini M, Garassino MC, Linardou H, Damia G, Wiesmüller L. Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer? Cancer Treat Rev. 2016 Jul; 48:8-19. PMID: 27262017.
      Citations: 13     Fields:    Translation:HumansCells
    211. Pelosi G, Pellegrinelli A, Fabbri A, Tamborini E, Perrone F, Settanni G, Busico A, Picciani B, Testi MA, Militti L, Maisonneuve P, Valeri B, Sonzogni A, Proto C, Garassino M, De Braud F, Pastorino U. Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules. Virchows Arch. 2016 Jun; 468(6):651-62. PMID: 27056568.
      Citations: 8     Fields:    Translation:Humans
    212. Marabese M, Caiola E, Garassino MC, Rastelli G, Settanni G, Brugnara S, Broggini M, Ganzinelli M. G48A, a New KRAS Mutation Found in Lung Adenocarcinoma. J Thorac Oncol. 2016 07; 11(7):1170-5. PMID: 27058911.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    213. Lo Russo G, Imbimbo M, Garassino MC. Is the chemotherapy era in advanced non-small cell lung cancer really over? Maybe not yet. Tumori. 2016 Jun 02; 2016(3):223-5. PMID: 26979246.
      Citations: 4     Fields:    Translation:Humans
    214. Lo Russo G, Pusceddu S, Proto C, Macerelli M, Signorelli D, Vitali M, Ganzinelli M, Gallucci R, Zilembo N, Platania M, Buzzoni R, de Braud F, Garassino MC. Treatment of lung large cell neuroendocrine carcinoma. Tumour Biol. 2016 Jun; 37(6):7047-57. PMID: 26943800.
      Citations: 29     Fields:    Translation:Humans
    215. Pusceddu S, Lo Russo G, Macerelli M, Proto C, Vitali M, Signorelli D, Ganzinelli M, Scanagatta P, Duranti L, Trama A, Buzzoni R, Pelosi G, Pastorino U, de Braud F, Garassino MC. Diagnosis and management of typical and atypical lung carcinoids. Crit Rev Oncol Hematol. 2016 Apr; 100:167-76. PMID: 26917456.
      Citations: 13     Fields:    Translation:Humans
    216. Lo Russo G, Proto C, Garassino MC. Afatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake? Transl Lung Cancer Res. 2016 Feb; 5(1):110-4. PMID: 26958504; PMCID: PMC4758965.
      Citations: 7     
    217. Pelosi G, Perrone F, Tamborini E, Fabbri A, Testi MA, Busico A, Settanni G, Picciani B, Bovio E, Sonzogni A, Valeri B, Garassino M, De Braud F, Pastorino U. Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections. Virchows Arch. 2016 Apr; 468(4):451-61. PMID: 26818831.
      Citations: 1     Fields:    Translation:Humans
    218. Scorsetti M, Trama A, D'Angelillo R, Serpico D, Macerelli M, Zucali P, Gatta G, Garassino MC, Leo F. Thymoma and thymic carcinomas. Crit Rev Oncol Hematol. 2016 Mar; 99:332-50. PMID: 26818050.
      Citations: 131     Fields:    Translation:Humans
    219. Pilotto S, Carbognin L, Karachaliou N, Garassino M, Cuppone F, Petraglia S, Rosell R, Tortora G, Bria E. Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer. Transl Lung Cancer Res. 2015 Dec; 4(6):704-12. PMID: 26798579; PMCID: PMC4700216.
      Citations: 4     
    220. Ganzinelli M, Rulli E, Caiola E, Garassino MC, Broggini M, Copreni E, Piva S, Longo F, Labianca R, Bareggi C, Fabbri MA, Martelli O, Fagnani D, Locatelli MC, Bertolini A, Valmadre G, Pavese I, Calcagno A, Sarobba MG, Marabese M. Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR). Sci Rep. 2015 Nov 17; 5:16331. PMID: 26573509; PMCID: PMC4648064.
      Citations: 7     Fields:    Translation:Humans
    221. Fabbri A, Papotti M, Rossi G, Cavazza A, Righi L, Tamborini E, Perrone F, Settanni G, Busico A, Testi MA, Maisonneuve P, De Braud F, Garassino M, Valeri B, Sonzogni A, Pastorino U, Pelosi G. Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge. J Thorac Oncol. 2015 Nov; 10(11):1560-9. PMID: 26317919.
      Citations: 13     Fields:    Translation:Humans
    222. Marabese M, Ganzinelli M, Garassino MC, Shepherd FA, Piva S, Caiola E, Macerelli M, Bettini A, Lauricella C, Floriani I, Farina G, Longo F, Bonomi L, Fabbri MA, Veronese S, Marsoni S, Broggini M, Rulli E. KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy. Oncotarget. 2015 Oct 20; 6(32):34014-22. PMID: 26416458; PMCID: PMC4741822.
      Citations: 50     Fields:    Translation:Humans
    223. Signorelli D, Macerelli M, Proto C, Vitali M, Cona MS, Agustoni F, Zilembo N, Platania M, Trama A, Gallucci R, Ganzinelli M, Pelosi G, Pastorino U, de Braud F, Garassino MC, Lo Russo G. Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy? Tumori. 2016 Jan-Feb; 102(1):18-30. PMID: 26481865.
      Citations: 3     Fields:    Translation:Humans
    224. Berardi R, Morgese F, Garassino MC, Cascinu S. New findings on thymic epithelial tumors: Something is changing. World J Clin Oncol. 2015 Oct 10; 6(5):96-8. PMID: 26468444; PMCID: PMC4600197.
      Citations: 2     
    225. Caiola E, Salles D, Frapolli R, Lupi M, Rotella G, Ronchi A, Garassino MC, Mattschas N, Colavecchio S, Broggini M, Marabese M, Wiesmüller L. Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells. Oncotarget. 2015 Oct 06; 6(30):30072-87. PMID: 26353932; PMCID: PMC4745782.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    226. Fabbri A, Tamborini E, Perrone F, Testi AM, Settanni G, Busico A, Centonze G, Braidotti P, Bulfamante G, De Braud F, Garassino M, Pastorino U, Pelosi G. Challenging Lung Carcinoma with Coexistent ?Np63/p40 and Thyroid Transcription Factor-1 Labeling Within the Same Individual Tumor Cells. J Thorac Oncol. 2015 Oct; 10(10):1500-2. PMID: 26398824.
      Citations: 9     Fields:    Translation:Humans
    227. Rulli E, Marabese M, Torri V, Farina G, Bettini A, Moscetti L, Ganzinelli M, Copreni E, Labianca R, Martelli O, Marsoni S, Broggini M, Garassino MC, TAILOR trialists, Veronese S, Longo F, Lauricella C. Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. Ann Oncol. 2015 Oct; 26(10):2079-84. PMID: 26209642.
      Citations: 27     Fields:    Translation:Humans
    228. Torri V, Broggini M, Garassino MC. Correction to Lancet Oncol 2015; 16: 747. EGFR mutations and EGFR tyrosine kinase inhibitors. Lancet Oncol. 2015 Jul; 16(7):e313. PMID: 26149882.
      Citations:    Fields:    
    229. Torri V, Broggini M, Garassino MC. EGFR mutations and EGFR tyrosine kinase inhibitors. Lancet Oncol. 2015 Jul; 16(7):746-8. PMID: 26051233.
      Citations: 1     Fields:    Translation:Humans
    230. Reckamp KL, Baas P, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR, Brahmer J, Crinò L, Arén Frontera O. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 09; 373(2):123-35. PMID: 26028407; PMCID: PMC4681400.
      Citations: 3788     Fields:    Translation:HumansCTClinical Trials
    231. Garassino MC, Marsoni S. A lesson from vorinostat in pleural mesothelioma. Lancet Oncol. 2015 Apr; 16(4):359-60. PMID: 25800895.
      Citations: 1     Fields:    Translation:Humans
    232. Garassino MC, Broggini M. Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?-An update incorporating the DELTA trial data. J Thorac Dis. 2015 Mar; 7(3):224-6. PMID: 25922695; PMCID: PMC4387444.
      Citations: 1     
    233. Haspinger ER, Agustoni F, Torri V, Gelsomino F, Platania M, Zilembo N, Gallucci R, Garassino MC, Cinquini M. Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. Crit Rev Oncol Hematol. 2015 May; 94(2):213-27. PMID: 25523487.
      Citations: 23     Fields:    Translation:Humans
    234. Serpico D, Trama A, Haspinger ER, Agustoni F, Botta L, Berardi R, Palmieri G, Zucali P, Gallucci R, Broggini M, Gatta G, Pastorino U, Pelosi G, de Braud F, Garassino MC. Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors. Ann Oncol. 2015 May; 26(5):838-847. PMID: 25411417.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    235. Platania M, Valeri B, Calareso G, Agustoni F, Haspinger E, Pusceddu S, Garassino MC, Gelsomino F, de Braud F, Marchianò A. Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer. Int J Colorectal Dis. 2015 Mar; 30(3):429-30. PMID: 25139369.
      Citations: 1     Fields:    Translation:Humans
    236. Casadio C, Ardissone F, Santambrogio L, Ratto GB, Garofalo G, Bedini AV, Garassino M, Porcu L, Torri V, Pastorino U, Bovolato P, Billè A. Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol. 2014 Mar; 9(3):390-6. PMID: 24518090.
      Citations: 48     Fields:    Translation:Humans
    237. Haspinger ER, Garassino MC, Torri V, Cinquini M, De Braud F, Gelsomino F. Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations? J Clin Oncol. 2014 Mar 10; 32(8):859-63. PMID: 24493720.
      Citations: 1     Fields:    Translation:Humans
    238. Garassino MC, Torri V. Afatinib for lung cancer: let there be light? Lancet Oncol. 2014 Feb; 15(2):133-4. PMID: 24439930.
      Citations: 1     Fields:    Translation:Humans
    239. Piva S, Ganzinelli M, Garassino MC, Caiola E, Farina G, Broggini M, Marabese M. Across the universe of K-RAS mutations in non-small-cell-lung cancer. Curr Pharm Des. 2014; 20(24):3933-43. PMID: 24138715.
      Citations: 20     Fields:    Translation:HumansAnimals
    240. Pelosi G, Haspinger ER, Bimbatti M, Leone G, Paolini B, Fabbri A, Tamborini E, Perrone F, Testi A, Garassino M, Maisonneuve P, de Braud F, Pilotti S, Pastorino U. Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases. Int J Surg Pathol. 2014 Apr; 22(2):136-48. PMID: 24326823.
      Citations: 1     Fields:    Translation:Humans
    241. Pessi MA, Zilembo N, Haspinger ER, Molino L, Di Cosimo S, Garassino M, Ripamonti CI. Targeted therapy-induced diarrhea: A review of the literature. Crit Rev Oncol Hematol. 2014 May; 90(2):165-79. PMID: 24373918.
      Citations: 16     Fields:    Translation:Humans
    242. Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M. Targeting the MET gene for the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol. 2014 Feb; 89(2):284-99. PMID: 24355409.
      Citations: 42     Fields:    Translation:HumansAnimals
    243. Bria E, Peretti U, Massari F, Garassino M, Pelosi G, Tortora G, Pilotto S. Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number. J Thorac Oncol. 2013 Dec; 8(12):e105-6. PMID: 24389444.
      Citations: 7     Fields:    Translation:Humans
    244. Rossi A, Torri V, Garassino MC, Porcu L, Galetta D. The impact of personalized medicine on survival: comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers. Cancer Treat Rev. 2014 May; 40(4):485-94. PMID: 24112813.
      Citations: 10     Fields:    Translation:Humans
    245. La Verde N, Lonardi S, Generali D, Moretti A, Atzori F, Cazzaniga M, Saggia C, Tondulli L, Marcon I, Gentile AL, Rossello R, Martelli O, Aglione S, Farina G, Cinquini M, Garassino M, Collovà E. Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers. Tumori. 2013 Sep-Oct; 99(5):596-600. PMID: 24362863.
      Citations: 2     Fields:    Translation:Humans
    246. Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S, TAILOR trialists. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013 Sep; 14(10):981-8. PMID: 23883922.
      Citations: 219     Fields:    Translation:Humans
    247. Agustoni F, Platania M, Vitali M, Zilembo N, Haspinger E, Sinno V, Gallucci R, de Braud F, Garassino MC. Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders. Cancer Treat Rev. 2014 Feb; 40(1):197-203. PMID: 23850197.
      Citations: 15     Fields:    Translation:HumansAnimals
    248. Garassino MC, Piva S, La Verde N, Spagnoletti I, Iorno V, Carbone C, Febbraro A, Bianchi A, Bramati A, Moretti A, Ganzinelli M, Marabese M, Gentili M, Torri V, Farina G. Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. PLoS One. 2013; 8(4):e59981. PMID: 23577077; PMCID: PMC3618180.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    249. Rossi G, Cavazza A, Righi L, Maisonneuve P, Barbareschi M, Graziano P, Pastorino U, Garassino M, de Braud F, Papotti M, Pelosi G. ?Np63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization. Int J Surg Pathol. 2013 Jun; 21(3):229-39. PMID: 23486764.
      Citations: 16     Fields:    Translation:Humans
    250. Di Maio M, Bria E, Banna GL, Puglisi F, Garassino MC, Lorusso D, Perrone F. Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors. Anticancer Drugs. 2013 Feb; 24(2):99-111. PMID: 23165435.
      Citations: 6     Fields:    Translation:Humans
    251. Garassino MC, Platania M, Broggini M, Torri V, De Braud F. To target or not to target, that is the question. J Clin Oncol. 2013 Mar 20; 31(9):1254. PMID: 23358979.
      Citations: 1     Fields:    Translation:Humans
    252. Broggini M, Garassino MC, Damia G. Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer. Cancer Manag Res. 2013; 5:15-20. PMID: 23378782; PMCID: PMC3559079.
      Citations: 1     
    253. Pietrantonio F, Garassino MC, Torri V, de Braud F. Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306. Ann Oncol. 2012 Oct; 23(10):2771-2772. PMID: 22875835.
      Citations: 1     Fields:    Translation:Humans
    254. Pelosi G, Gasparini P, Cavazza A, Rossi G, Graziano P, Barbareschi M, Perrone F, Barberis M, Takagi M, Kunimura T, Yamada T, Nakatani Y, Pastorino U, Scanagatta P, Sozzi G, Garassino M, De Braud F, Papotti M. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. Lung Cancer. 2012 Sep; 77(3):507-14. PMID: 22705117.
      Citations: 29     Fields:    Translation:Humans
    255. Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Follador A, Lo Dico M, Moretti A, De Vincenzo F, Lorenzi E, Perrino M, Giordano L, Farina G, Santoro A, Garassino M, Collovà E. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer. 2012 Mar; 75(3):360-7. PMID: 21937142.
      Citations: 23     Fields:    Translation:Humans
    256. Garassino MC, Marsoni S, Floriani I. Testing epidermal growth factor receptor mutations in patients with non-small-cell lung cancer to choose chemotherapy: the other side of the coin. J Clin Oncol. 2011 Oct 01; 29(28):3835-7; author reply 3837-9. PMID: 21876080.
      Citations: 4     Fields:    Translation:Humans
    257. Novello S, Milella M, Tiseo M, Banna G, Cortinovis D, Di Maio M, Garassino M, Maione P, Martelli O, Bria E, Vavalà T. Maintenance therapy in NSCLC: why? To whom? Which agent? J Exp Clin Cancer Res. 2011 May 06; 30:50. PMID: 21548925; PMCID: PMC3113744.
      Citations: 9     Fields:    Translation:Humans
    258. Farina G, Longo F, Martelli O, Pavese I, Mancuso A, Moscetti L, Labianca R, Bertolini A, Cortesi E, Farris A, Fagnani D, Locatelli MC, Valmadre G, Ardizzoia A, Tomirotti M, Rulli E, Garassino MC, Scanni A. Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations. Clin Lung Cancer. 2011 Mar; 12(2):138-41. PMID: 21550561.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    259. Lurati C, Riva M, Resega R, Mantica C, Garassino MC, Sburlati P, La Verde N, Cinquini M, Piva S, Mencacci C, Farina G. A mono-institutional prospective study on the effectiveness of a specialist psychotherapeutic intervention (POI) started at the diagnosis of cancer. Support Care Cancer. 2012 Mar; 20(3):475-81. PMID: 21258946.
      Citations: 3     Fields:    Translation:Humans
    260. Garassino MC, Marabese M, Rusconi P, Rulli E, Martelli O, Farina G, Scanni A, Broggini M. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann Oncol. 2011 Jan; 22(1):235-237. PMID: 21169473.
      Citations: 93     Fields:    Translation:HumansCells
    261. Galfrascoli E, Piva S, Cinquini M, Rossi A, La Verde N, Bramati A, Moretti A, Manazza A, Damia G, Torri V, Muserra G, Farina G, Garassino MC, ORION Collaborative Group. Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis. 2011 Apr; 43(4):286-94. PMID: 21146479.
      Citations: 25     Fields:    Translation:Humans
    262. Garassino MC, Torri V, Michetti G, Lo Dico M, La Verde N, Aglione S, Mancuso A, Gallerani E, Galetta D, Martelli O, Fatigoni S, Ghidini A, Saggia C, Bareggi C, Rossi A, Farina G, Thatcher N, Blackhall F, Lorigan P, Califano R, Collovà E. Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. Lung Cancer. 2011 Jun; 72(3):378-83. PMID: 20950888.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    263. Mancuso A, Sacchetta S, Saletti PC, Tronconi C, Milesi L, Garassino M, Martelli O, Leone A, Zivi A, Cerbone L, Recine F, Sollami R, Labianca R, Cavalli F, Sternberg CN. Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey. Anticancer Res. 2010 Oct; 30(10):4289-95. PMID: 21036754.
      Citations: 11     Fields:    Translation:Humans
    264. Floriani I, Garassino MC, Broggini M, Veronese S, Marsoni S, Marabese M, Farina G, Scanni A. Role of cetuximab in the treatment of patients with NSCLC: are we throwing out the baby with the bath water? J Clin Oncol. 2010 Sep 20; 28(27):e467; author reply e468. PMID: 20585086.
      Citations:    Fields:    Translation:Humans
    265. Garassino MC, Cinquini M, Sburlati P, Di Maio M, Farina G, Gridelli C, Torri V, Rossi A. Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer. 2010 Nov; 70(2):119-28. PMID: 20188431.
      Citations: 26     Fields:    Translation:Humans
    266. Abidin AZ, Garassino MC, Califano R, Harle A, Blackhall F. Targeted therapies in small cell lung cancer: a review. Ther Adv Med Oncol. 2010 Jan; 2(1):25-37. PMID: 21789124; PMCID: PMC3126006.
      Citations: 20     
    267. Roila F, Garassino MC, Ballatori E. Cetuximab for metastatic colorectal cancer. N Engl J Med. 2009 Jul 02; 361(1):95; author reply 96-7. PMID: 19579279.
      Citations: 1     Fields:    Translation:Humans
    268. Garassino MC, Borgonovo K, Rossi A, Mancuso A, Martelli O, Tinazzi A, Di Cosimo S, La Verde N, Sburlati P, Bianchi C, Farina G, Torri V. Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Anticancer Res. 2009 Jul; 29(7):2691-701. PMID: 19596948.
      Citations: 11     Fields:    Translation:Humans
    269. Ripamonti CI, Farina G, Garassino MC. Predictive models in palliative care. Cancer. 2009 Jul 01; 115(13 Suppl):3128-34. PMID: 19544541.
      Citations: 11     Fields:    Translation:Humans
    270. La Verde N, Bareggi C, Garassino M, Borgonovo K, Sburlati P, Pedretti D, Bianchi C, Perrone S, Mihali D, Cobelli S, Mantica C, Rizzo A, Farina G. Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution. Support Care Cancer. 2008 Nov; 16(11):1311-5. PMID: 18663482.
      Citations: 9     Fields:    Translation:Humans
    271. Labianca R, Sburlati P, Quadri A, Garassino MC. Perioperative or postoperative therapy for resectable gastric cancer? Ann Oncol. 2008 Jul; 19 Suppl 5:v99-102. PMID: 18611910.
      Citations:    Fields:    Translation:Humans
    272. Garassino MC, Farina G, Rossi A, Martelli O, Torri V. Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab? J Clin Oncol. 2008 May 20; 26(15):2600; author reply 2601-2. PMID: 18487581.
      Citations: 3     Fields:    Translation:Humans
    273. Martelli O, Garassino M, Sacchetta S, Caristo R, Zivi A, Cerbone L, Mancuso A. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT). Anticancer Res. 2008 May-Jun; 28(3B):1767-71. PMID: 18630457.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    274. Roila F, Garassino MC, Mantica C. Cetuximab for colorectal cancer. N Engl J Med. 2008 Mar 13; 358(11):1196; author reply 1196-7. PMID: 18340662.
      Citations:    Fields:    Translation:Humans
    275. Labianca R, Garassino M, Torri V. Predicting response of molecular targeted therapies: a still possible challenge? Ann Oncol. 2008 May; 19(5):829-30. PMID: 18296420.
      Citations:    Fields:    Translation:Humans
    276. La Verde N, Garassino M, Bareggi C, Sburlati P, Borgonovo K, Dimaiuta M, Mantica C, Perrone S, Torri V, Farina G. An oxaliplatin + 5-fluorouracil bolus + folinic acid (BFOL) regimen as first-line treatment in metastatic colorectal cancer patients. Tumori. 2007 Nov-Dec; 93(6):557-61. PMID: 18338489.
      Citations:    Fields:    Translation:Humans
    277. La Verde N, Garassino MC, Spinelli G, Scanni A, Sburlati P, Farina G, Labianca R. Reversible palpebral ptosis following oxaliplatin infusion. Dig Liver Dis. 2007 Nov; 39(11):1041. PMID: 17913604.
      Citations: 2     Fields:    Translation:Humans
    278. Roila F, Garassino M, Fatigoni S. New anti-emetic treatments. Ann Oncol. 2007 Jul; 18 Suppl 9:ix43-7. PMID: 17631595.
      Citations:    Fields:    Translation:Humans
    279. Farina G, Garassino MC, Gambacorta M, La Verde N, Gherardi G, Scanni A. Response of thymoma to cetuximab. Lancet Oncol. 2007 May; 8(5):449-50. PMID: 17466903.
      Citations: 25     Fields:    Translation:Humans
    280. Garassino MC, Hollander L, Torri V. Bevacizumab for non-small-cell lung cancer. N Engl J Med. 2007 Mar 29; 356(13):1373; author reply 1374-5. PMID: 17392310.
      Citations: 1     Fields:    Translation:Humans
    281. Labianca R, La Verde N, Garassino MC. Development and clinical indications of cetuximab. Int J Biol Markers. 2007 Jan-Mar; 22(1 Suppl 4):S40-6. PMID: 17520580.
      Citations: 8     Fields:    Translation:HumansAnimals
    282. Labianca R, La Verde N, Garassino MC. Development and clinical indications of cetuximab. Int J Biol Markers. 2007 S4 - Jan-Mar; 22(4):40-46. PMID: 28207113.
      Citations: 1     Fields:    
    283. Labianca R, Mosconi S, Garassino MC. New strategies in colon cancer adjuvant therapy. Ann Oncol. 2006 Jun; 17 Suppl 7:vii51-4. PMID: 16760294.
      Citations: 2     Fields:    Translation:Humans
    284. Bareggi C, Paleari D, Garassino MC, Mora M, Salamina S, Senecione M, Ghidini A, Pancera G. Localized hand-foot syndrome after intra-arterial hepatic chemotherapy with floxuridine: a clinical case. Tumori. 2005 Mar-Apr; 91(2):193-6. PMID: 15948551.
      Citations:    Fields:    Translation:Humans
    285. Pancera G, Secondino S, Mastore M, Garassino MC. [Locoregional therapy in hepatic metastases of colorectal cancer]. Tumori. 2001 Jan-Feb; 87(1 Suppl 1):S70-2. PMID: 11300033.
      Citations:    Fields:    Translation:Humans
    Garassino's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (496)
    Explore
    _
    Co-Authors (16)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _